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 ABSTRACT 
 
Bone is one of the most common sites of distant metastases from breast 
carcinoma. In lytic bone metastasis, tumor associated-osteoclasts are the main 
actors of bone resorption. Under physiological conditions, osteoclast formation 
is activated by cytokines and hormones produced by bone-resident cells, 
including osteoblasts and mesenchymal stem cells. However, when tumor cells 
spread to the bone, they disrupt the delicate balance between cells orchestrating 
osteoclast formation, thereby promoting bone resorption. Current treatments of 
metastatic bone disease are largely ineffective to improve patient survival, 
possibly due to their inability to interfere with the metabolic pathways that 
regulate the behavior and the cross-talk between cancer cells and osteoclasts. To 
add news insights into the complex pathogenesis of osteolytic metastases, we 
focused our investigations on the role of lactate in the metabolic symbiosis of 
bone metastasis. We found that human osteoclasts are characterized by an 
increased mitochondrial metabolism, that probably supports the biosynthetic 
needs for osteoclast formation and activation, and that a glycolytic switch 
support the resorption activity of osteoclasts. Moreover, osteoclasts are able to 
uptake lactate from the extracellular space, an energy-rich metabolite produced 
by the glycolytic metabolism of breast carcinoma cells. In osteoclasts, lactate 
fuels oxidative metabolism, thereby increasing tumor aggressiveness. However, 
the bone metastatic microenvironment is composed of several types of cells, 
including tumor-associated stromal cells, bone-resident cells, tumor cells, and 
cancer-initiating cells. Each cell type takes part to the complex process of 
metastatic lesions formation. In particular, cancer stem cells play a primary role 
in tumorigenesis. To gain a more in-depth knowledge on the interplay between 
cells of tumor bulk, we validated the most stable housekeeping genes for gene 
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expression analysis on cancer stem cells. These findings lay the groundwork for 
future investigations on the cross-talk between stroma and tumor cells of the 
metastatic microenvironment. 
 6
Figure legend 
Figure 1.1. Osteoclast differentiation from hematopoietic precursor cells. 
Figure 1.2. Cellular elements of bone metastatic microenvironment. 
Figure 1.3. CSC model. 
Figure 4.1. Human osteoclasts show an increased mitochondrial mass. 
Figure 4.2. Ultrastructural analysis of mitochondria. 
Figure 4.3. Mitochondria of mature osteoclasts are organized in tubular 
structures. 
Figure 4.4. Mitochondria network in mature osteoclast. 
Figure 4.5. Expression of enzymes of the respiratory chain and total ATP 
intracellular content. 
Figure 4.6. Energetic metabolism during osteoclast differentiation. 
Figure 4.7. Glycolysis drives the activity of human osteoclasts. 
Figure 4.8. MCT expression increases during osteoclastogenesis and is relevant 
in the pathogenesis of giant-cell tumor of bone.   
Figure 4.9. MCT expression in breast carcinoma cells, MSC and osteoblasts. 
Figure 4.10. Lactate is an oxidative fuel for mature osteoclasts. 
Figure 4.11. Characterization of spheres obtained from MG-63, MDA-MB-231 
and ACHN cell lines.   
Figure 4.12. Transcription profile of selected reference genes. 
Figure 4.13. GeNorm evaluation of the minimal number of genes and validation 
of the identified top-ranked HKG genes for qRT-PCR normalization. 
Figure 4.14. Validation of the identified housekeeping genes. 
 7
Figure 5.1. Lactate exchange between highly glycolytic cells and osteoclasts in 
bone microenvironment supports tumor aggressiveness. 
 
 
Table legend 
Table 3.1. Candidate HKG genes.     
Table 4.1. Transcriptome data from deep sequencing analysis of CSC and native 
osteosarcoma cells. 
Table 4.2. Ct values of candidate HKG genes in CSC and native cell lines.  
Table 4.3. Ranking of the stability of expression of candidate reference genes by 
NormFinder, geNorm, and CV analyses. 
Table 4.4. Ranking of the stability of expression of candidate reference genes by 
NormFinder, geNorm, and CV analyses in CSC and native cells from 
carcinomas and sarcomas. 
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18S rRNA: 18S ribosomal RNA 
α-MEM: alpha-Modified Eagle’s Medium 
ΔCt: delta cycle threshold 
ACTB: actin, beta 
ATP: adenosine triphosphate 
B2M: beta-2-microglobulin 
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BMP: bone morphogenetic protein 
CAF: cancer-associated fibroblast 
CHC: alpha-cyano-4-hydroxy-cinnamate 
CSC: cancer stem cell 
COXII: cytochrome c oxidase subunit II, mitochondrial 
CV: coefficient of variation 
Ct: threshold cycles 
DMEM: dulbecco's modified eagle medium 
ECAR: extracellular acidification rate  
FBS: fetal bovine serum 
FCCP: carbonyl cyanide 4-trifluoromethoxy phenylhydrazone  
FGF: fibroblast growth factor 
G6PD: glucose-6-phosphate dehydrogenase 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GCT: giant-cell tumor of bone 
GUSB: beta-glucuronidase 
HKG: housekeeping gene 
HMBS: hydroxymethylbilane synthase 
HPRT1: hypoxanthine phosphoribosyltransferase 1 
HSP60: heat shock protein 60 kDa 
IGF-1: insulin-like growth factor-1 
IGF-2: insulin-like growth factor-2 
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IMDM: Iscove’s modified Dulbecco’s medium 
Km: Michealis Menten constant 
LDH: lactate dehydrogenase 
M-CSF: macrophage colony-stimulating factor 
MCT1: monocarboxylate transporter 1 
MCT2: monocarboxylate transporter 2 
MCT3: monocarboxylate transporter 3 
MCT4: monocarboxylate transporter 4 
MCT8: monocarboxylate transporter 8 
MCT10: monocarboxylate transporter 10 
MtOCR: mitochondrial OCR  
NDUFB8: NADH dehydrogenase [ubiquinone] beta subcomplex subunit 8, 
mitochondrial 
NFkB: nuclear factor-kappa B  
OCR: oxygen consumption rate 
OPG: osteoprotegerin  
OPN: osteopontin  
OXPHOS: oxidative phosphorylation  
PBMC: peripheral blood mononuclear cells   
PCR: polymerase chain reaction 
PDGF: platelet-derived growth factor 
PET: positron emission tomography 
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PGC-1β: peroxisome proliferator-activated recepto-γ coactivator 1β  
PGK1: phosphoglycerate kinase 1 
PPIA: peptidylprolyl isomerase A (cyclophilin A) 
PTH: parathyroid hormone 
PTHrP: parathyroid hormone-related peptide 
qRT-PCR: quantitative real time polimerase chain reaction 
RANKL: receptor activator of nuclear factor-kappa B ligand 
RIN: RNA Integrity Number 
ROI: region of interest  
RPL13a: ribosomal protein L13a 
SEM: standard error of mean 
SD: standard deviation 
SDHA: succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 
SDHB: Succinate dehydrogenase complex iron sulfur subunit B, mitochondrial 
SLC: solute carrier 
SDpooled : pooled standard deviation 
TAT1: T-Type amino acid transporter 1 
TBP: TATA-binding protein 
TCA: tricarboxylic acid  
TGF-β: transforming growth factor beta 
TRAP: tartrate-resistant acid phosphatase 
TUBB: tubulin, beta class I 
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UQCRC2: Ubiquinol-cytochrome C reductase core protein II, mitochondrial 
V-ATP5A: ATP synthase subunit alpha, mitochondrial 
V-ATPases: vacuolar H(+)-ATPases 
YWHAZ: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein zeta polypeptide  
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1. INTRODUCTION 
 
1.1  Metastatic bone disease  
Cancer progression to metastasis is of dismal prognosis. Metastases derive from 
the dissemination and growth of neoplastic cells from the primary tumor to 
distant organs and tissues in the body. Bone is the most common site of 
metastases from solid tumors, and bone metastases are far more frequent than 
primary tumors of bone. Approximately 14 millions of new cancer cases are 
diagnosed each year worldwide [1], and up to 70% develop skeletal metastases 
[2].  
Bone is a metabolically dynamic tissue that undergoes continuous remodeling 
throughout life. Bone homeostasis is maintained through a delicate balance 
between bone formation and resorption, mediated by bone-forming osteoblasts 
and bone-resorbing osteoclasts [3]. This coupling process is lost when cancer 
metastasizes to the bone [4]. An ample body of work has been performed to 
elucidate the key factors that are accountable for the loss of equilibrium between 
bone formation and bone resorption, which is responsible for the deleterious 
complications associated with bone metastases. Although in the early stages 
bone metastases can be asymptomatic, they are a devastating complication for 
most patients with advanced cancer. Lytic bone metastases are associated with a 
significant degree of morbidity related to osteolysis. The skeletal-related events 
result in intractable pain and other local complications, such as pathological 
fracture, spinal cord, and nerve root compression [5]. In the late phases of the 
disease, extensive bone destruction can lead to hypercalcemia, the most rapidly 
fatal complication of bone metastases [6]. All the skeletal-related events of 
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metastatic bone disease result in restricted mobility, greatly reducing the 
patient’s quality of life.  
The management of patients with bone pain is multidisciplinary, including the 
use of analgesia, radio/chemotherapy, surgery, hormone therapy, opioids, and 
bisphosphonates (pamidronate and zeledronic acid). Analgesia, based on the use 
of non-steroidal anti-inflammatory drugs, is the first option in most patients, 
progressing to opioids as the intensity of pain increases. These agents produce 
several side effects, such as nausea, sedation, and constipation. Surgery can be 
used for localized metastatic disease, and hemibody radiation might be curative 
for patients with disease extending to one region of the body. In patients with 
widespread bone metastases, radiopharmaceuticals provide pain-control. 
However, current therapies are mainly palliative: to date, no effective treatment 
has been developed that is able to specifically target bone metastases.  
 
1.1.1 Normal bone physiology 
To understand the microenvironment of osteolytic metastases, an overview of 
the basic structure and function of bone is necessary. 
Bone is the main structural and supportive connective tissue of the body. The 
majority of bone is formed by bone matrix, composed primarily of Type I 
collagen mineralized with hydroxyapatite crystals. Within these mineralized 
structure are trapped numerous growth factors, which are released upon bone 
resorption. The normal osseous tissue is composed by cortical and trabecular 
bone. The cortical or compact bone is the supporting part of the skeleton, made 
up of a dense layer of bone tissue. The trabecular or cancellous bone is the 
porous, metabolically dynamic part of bone matrix, typically located at the ends 
of long bones and within vertebrae. Under normal conditions, bone continually 
undergoes remodeling in a coupled and sequential process of osteoclast-
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mediated bone resorption and osteoblast-mediated bone deposition. This 
remodeling cycle is tightly regulated to maintain bone structure and calcium 
homeostasis. To this purpose, many hormones and protein factors are involved 
in the cross-talk between osteoclasts, osteoblasts and other cells of bone 
microenvironment [7].  
 
1.1.1.1 Osteoblast biology 
Osteoblasts are mononuclear bone-forming cells with the specific function of 
regulating bone mineralization and synthesizing collagen precursors of bone 
matrix that form osteoid.  
Osteoblasts derive from bone marrow mesenchymal stem cells (MSC). MSC 
proliferate and form pre-osteoblasts that differentiate into osteoblasts when 
stimulated by bone morphogenic proteins (BMP) and other growth factors. 
Afterwards, osteoblasts become osteocytes when trapped and surrounded by the 
bone matrix that they produce.  
Osteoblasts take part in the control of osteoclast differentiation through the 
expression of the receptor activator of nuclear factor-kappa B (NFkB) ligand 
(RANKL), and the secretion of osteoprotegerin (OPG), a decoy RANKL 
receptor that blinds to RANK and inhibits osteoclast formation and activity. 
Osteblasts express on they surface different other molecules that are important 
for bone regulation, including parathyroid hormone (PTH) receptors, estrogen, 
vitamin D3, and different cytokines [8]. Several factors, such as PTH, 
prostaglandin E (PGE), fibroblast growth factor (FGF), transforming growth 
factor beta (TGF-β), and RANKL have been shown to stimulate both resorption 
and formation of bone. Notably, PTH is the only known agent that is currently 
available for pharmacological stimulation of bone formation [9].   
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1.1.1.2 Osteoclast biology 
Osteoclasts are giant, multinucleated, non-proliferative bone-resorbing 
polykaryons formed by the differentiation and fusion of hematopoietic stem 
cells (HSC) of the monocyte-macrophage lineage [10]. As shown in figure 1.1, 
these precursor cells differentiate into pre-osteoclasts, which fuse to form 
inactive osteoclasts. These are then activated, and became mature osteoclasts 
that are prone to resorb bone. The process is supported by two essential 
cytokines, the macrophage colony-stimulating factor (M-CSF) [11] and RANKL 
[12-14]. RANKL, in the presence of M-CSF, promotes the fusion of precursor 
cells to form multinucleated osteoclasts. In addition to RANKL, osteoblasts and 
several other cell types of bone microenvironment produce OPG, the decoy 
protein for RANK. The RANKL/OPG ratio is a central regulator of osteoclast 
differentiation at different steps, also involved in the activation of mature 
osteoclasts to resorption [15]. 
 
 
Figure 1.1. Osteoclast differentiation from hematopoietic precursor cells. Multiple 
molecules within the bone microenvironment drive osteoclastogenesis, including M-CSF, 
RANKL and OPG. RANKL and OPG levels regulate osteoclast differentiation at different 
steps. 
 
It is accepted that osteoclast differentiation is orchestrated by these cytokines 
that are locally produced by osteoblasts, MSC and other cells of bone 
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microenvironment [16-18], as well as by growth factors [19], and systemic 
hormones [20]. Beside protein factors, osteoclastogenesis is also regulated by 
the modulation of physical conditions of bone microenvironment. In particular, 
reduced oxygen tension is a general stimulator of cells derived from marrow 
precursors [21]. Previous studies have elucidated that hypoxia is a potent 
stimulator of osteoclast differentiation when combined with periods of re-
oxygenation [22], and increases osteoclast-mediated bone resorption [23], 
although it reduces the viability of mature osteoclasts [24,25]. Hypoxia is also 
associated with local acidosis, and reduced pH is an additional activator of 
mature osteoclast functions [26]. As a consequence, hypoxia and low pH are 
general features of various osteoclast-associated skeletal diseases [27,28].  
More recent findings have elucidated that energy metabolism plays a central role 
in osteoclastogenesis and in the regulation of osteoclast activation to resorption 
[29]. Osteoclastogenesis is an energy-consuming process: the serial process of 
osteoclast differentiation from hematopoietic precursor cells requires high 
metabolic activity and ATP production [29,30] for proliferation of precursors, 
migration, and fusion to form multinuclear cells. Jin and colleagues have 
demonstrated that the presence of intact mitochondria is mandatory for 
osteoclastogenesis [31]. Mature osteoclasts are mitochondria-rich cells [32,33], 
which exhibit high expression of tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation (OXPHOS) enzymes [34]. As confirmation, deletion of the co-
trascriptional factor PGC-1β in osteoclast precursors impairs osteoclast 
differentiation and mitochondrial biogenesis [35-37], outlining the importance of 
functional mitochondria in these cells [38].  
 
1.1.1.3 Mechanism of osteoclast-mediated bone resorption 
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The specialized role of mature osteoclast is to polarize onto bone, bind to bone 
matrix via integrin proteins, and secrete acid and lysosomal enzymes in the 
extracellular resorption lacunae, which dissolve both inorganic and organic 
components of the bone matrix [39].  
When osteoclasts are activated for resorption, they first reorganize the 
cytoskeleton to support its activity [40,41]. Podosomes mediate the attachment 
of osteoclasts to the extracellular matrix via the αvβ3 integrin [42], and 
contribute to form circular structures in the plasma membrane facing the bone 
matrix [43]. Podosomes disappear when F-actin forms the characteristic ring-
like structures close to the bone facing plasma membrane. Ultrastructure of the 
sealing zone area reveals a tight attachment of osteoclasts to the bone surface via 
integrins, and this structure demarcates actual resorption areas [43].  
After attachment of osteoclasts to the mineralized matrix, osteoclasts polarize 
the plasma membrane to form two specific membrane domains, the ruffled 
border and the functional secretory domain. The ruffled border membrane is the 
resorbing organ of osteoclasts. Osteoclasts activated to resorption secrete a large 
amount of acidic intracellular vesicles, which fuse with the plasma membrane 
facing to the bone surface inside the actin ring [44]. The process of osteoclast-
mediated bone resorption demands the secretion of large amounts of protons and 
hydrochloric acid mediated by proton pumps, such as the vacuolar H(+)-
ATPases (V-ATPases), to dissolve hydroxyapatite crystals, and the synthesis and 
secretion of proteases that degrades collagen fibers. During bone destruction, 
osteoclasts migrate along the bone surface, and support endocytosis and 
transcytosis of degradation products from the resorption lacunae [45-47]. In 
order to fulfill these functions, osteoclasts require high energy, considerable ion 
movement, and intense intracellular replacement of membrane material via 
vesicular trafficking. The activity of V-ATPases to pump protons in the 
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resorption lacunae is also an energy-consuming process, which requires high 
amounts of ATP [48].  
 
1.1.2 The evolution of tumor metastasis 
Metastasis is the final stage of tumor progression. Although the genetic basis of 
tumorigenesis can greatly vary, the steps of metastasis are similar in all tumors. 
Cancer evolution to metastasis is a multi-step process including multiple barriers 
to cancer cell dissemination. Cells from the primary tumor detach from adjacent 
cells, and invade the adjacent tissue in the primary organ (invasion). These cells 
then enter into tumor capillaries (intravasation), and via these capillaries reach 
the general circulation to colonize secondary sites (extravasation) [49]. Each of 
these steps represent cell interactions caused by specific characteristics of both 
tumor cells and the surrounding tissue [50].  
Angiogenesis is the first and essential step for both the growth of the primary 
tumor and the metastatic process. Vascularization increases the supply of 
nutrients to tumors and the chance for tumor cells to migrate into tumor 
capillaries. The process of migration of cells into tumor capillaries (invasion) is 
stimulated by angiogenic factors produced by the tumor, and involve the 
adhesion of tumor cells to the basement membrane through adhesion molecules, 
and the secretion of matrix proteases and proteolytic enzymes to disrupt the 
basement membrane. Tumor cells in the circulation must overcome the stress 
imposed by hemodynamic shear forces and the assault by natural killer cells. 
Only a few, heavy-duty cells survive to circulation and arrive at the secondary 
site.  
The process of migration of tumor cells into blood vessels at the primary tumor 
site are analogous to those involved in the migration from vasculature to the 
bone marrow cavity (extravasion). The extravasion process involves the 
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adhesion of tumor cells to other cells and matrix proteins of the secondary site, 
and the subsequent adaptation to foreign tissue microenvironment. In bone, 
tumor cells actively proliferate and adapt to grow [49,51]. 
 
1.1.3 Pathophysiology of bone metastasis  
Metastases to bone frequently affect the axial skeleton, the anatomic site of red 
marrow in adults. Some authors have suggested that the distribution pattern of 
bone metastases could be in part justified by the pattern of distribution of 
regional venous drainage [52]. However, tumors also metastasize to distant 
organs that cannot be expected based on blood flow patterns. Most evidence 
suggests that not only the properties of circulation, but rather cells-to-cells and 
cell-to-extracellular matrix interactions within the axial skeleton could assist 
cancer cells in the formation of bone metastases [5,53,54]. The process is 
regulated by the activation of specific genes and by protein factors such as 
chemokines or motility factors. In summary, the formation of bone metastases is 
influenced by physical and cellular elements of the local region, suggesting that 
the specific site of spread of tumor cells is not only randomly determined by 
blood flow. This not-random concept for tumor metastases formation was 
proposed over a century ago by Stephen Paget [55], who referred to the 
phenomenon of tumor spread to specific sites in the body as the “seed and soil” 
hypothesis. Indeed, although virtually any malignancy can metastasize to bone, 
breast and prostate cancers display a particular osteotropism [6,56], an 
exceptional affinity to metastasize and grow in bone, which accounts for about 
65-80% of skeletal metastases [57]. The mechanism underlying cancer 
organotropism are various and involve distinctive characteristics of both 
carcinoma cells that enable the growth in bone [58], and the bone 
microenvironment that provides a fertile soil onto which to grow.  
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1.1.4 Types of bone metastases 
The most common human adult carcinomas metastasize with avidity to bone. In 
particular, breast and prostate carcinoma are the two tumor types those most 
commonly metastasize to the skeleton. Breast cancer predominantly causes 
osteolytic metastases, characterized by increased bone loss, whereas prostate 
cancer classically causes osteoblastic (or osteosclerotic) lesions associated with 
abnormal new bone formation [59]. In lytic bone metastases, bone loss is 
associated with osteolysis caused mainly by osteoclast stimulation, or by a 
marginally osteolytic action of cancer cells on bone, and is related to reduced 
osteoblast functions that are uncoupled with bone resoprtion [59,60]. However, 
the situation is more complex, and both processes are typically present, 
ultimately tipping the balance to bone loss, gain or the mix of two lesions. In 
fact, although breast cancer commonly results in osteolytic lesions, about 25% 
of patients also exhibit osteoblastic lesions [54].  
 
1.2 Microenvironment of osteolytic metastases 
The complex process of tumor metastasis involves reciprocal interplay between 
cancer cells and host stroma, and is strongly influenced by microenvironmental 
factors.  
The active cross-talk between the bone microenvironment and breast tumor cells 
promotes a vicious cycle that contributes to cell proliferation and bone 
destruction [61-63]. In this vicious cycle, tumor cells, once established in bone, 
secrete factors and cytokines that promote osteoclast-mediated bone resorption. 
In turn, osteoclast activity stimulates tumor cells proliferation by the release of 
numerous proteic factors embedded in the bone matrix that act on cancer cells, 
thereby promoting bone destruction and a more aggressive phenotype of tumor 
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cells [59,60]. The following paragraphs will discuss how metastatic cancer cells 
affect bone microenvironment to support their proliferation and the formation of 
lytic bone lesions.  
 
1.2.1 Cellular elements of bone metastatic microenvironment  
Bone microenvironment is a complex structural and biological system that holds 
hematopoietic and mesenchymal cells of multiple lineages, the bone marrow 
stroma, the bone matrix and a sinusoidal blood supply. Many of these elements 
enhance the proliferation of tumor cells and the formation of osteolytic lesions. 
First, physical factors within the bone microenvironment may promote tumor 
growth, including low oxygen tension, acidic pH, and elevated extracellular 
calcium and phosphate levels. Second, many growth factors stored in the bone 
matrix contribute to tumor cell proliferation, including TGF-β and insulin-like 
growth factor-I (IGF-I) and II (IGF-II). Finally, and probably most importantly, 
transient cells and bone-resident cells, including osteoclasts, osteoblasts, and 
osteocytes, may directly sustain tumor growth  [62]. Transient cells include 
erythrocytes, myeloid and immune T cells, platelets, bone marrow 
hematopoietic and endothelial cells, and other cells of the immune system, as 
well as bone marrow-derived mesenchymal stem cells. All of these cells may 
support tumor growth and metastases through different pathways [64,65], and 
some them are thought to take part in the formation of the pre-metastatic niche 
[65,66]. The role of bone resident cells in promoting tumor proliferation and 
osteoclast activation in osteolytic metastases will be discussed in the next 
sections. Moreover, an increasing body of evidence suggests that cancer stem 
cells (CSC), a small subset of stem-like elements within the tumor mass, sustain 
tumor progression from tumor initiation to the formation of local and distant 
metastases [67].  
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Figure 1.2 illustrates the complex microenvironment of lytic bone metastases. 
The metastatic microenvironment holds many cellular elements that contribute 
to the formation of osteolytic metastases. As mentioned above, tumor cells 
interact with stroma and bone resident cells, including osteoclasts, to support 
tumor cells proliferation, osteoclast differentiation and bone resorption, thereby 
promoting the formation of osteolytic lesions. CSC sustain metastasis as well, 
through several direct and indirect molecular and cellular mechanisms [68-70]. 
CSC are thought to reside in the metastatic niche [71] formed by tumor-
associated stromal cells, differentiated tumor cells, and bone resident cells. Both 
stromal and tumor cells orchestrate the process of self-renewal of CSC and their 
differentiation in tumor cells. Stromal cells produce and secrete proteic factors 
inducing CSC self-renewal, while tumor cells secrete factors that negatively 
impact on CSC self-renewal, thereby promoting their differentiation in tumor 
cells.  
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Figure 1.2. Cellular elements of bone metastatic microenvironment. In lytic bone 
metastasis, differentiated tumor cells, cancer stem cells (CSC), osteoclasts, and stromal cells 
interact to promote osteolytic lesions. CSC are a small subset of stem-like cells of the tumor 
mass. The proliferation of CSC is in part supported by proteic factors secreted by stromal 
cells.  
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1.2.1.1 Bone-resident cells sustain osteolytic metastases 
In osteolytic metastases, the process of osteoclast differentiation and activation 
to resorption is supported not only by osteoblsts and MSC, but notably also by 
tumor cells that spread to bone. Breast cancer cells produce and secrete 
numerous osteotropic factors supporting osteoclastogenesis and osteoclast 
activity. The process of osteoclast stimulation can be mediated by cytokines 
released in the tumor microenvironment by tumor cells that induce osteoclast 
and their precurosor cells either directly or indirectly, through factors that 
stimulate osteoblast and MCS to release pro-osteoclastogenic cytokines 
[17,72,73]. One of the main activators of osteoclast activity is the parathyroid 
hormone-related peptide (PTHrP), which is expressed by up to 90% of 
metastatic human breast cancers [74]. Tumor-derived factors such as PTHrP 
bind to receptors expressed on osteoblasts and upregulate the expression of 
RANKL and M-CSF by cells of the osteoblastic lineage, i.e. osteoblast 
precursors, osteoblasts, and osteocytes. In turn, RANKL binds to its receptor 
RANK on osteoclast precursors to promote osteoclast recruitment and 
formation, as well as on mature osteoclasts to activate osteoclast-mediated bone 
resorption [75]. Osteoclast activity triggers the release of matrix-stored growth 
factors and cytokines, including TGF-β, IGFs, platelet-derived growth factor 
(PDGF), bone morphogenetic proteins (BMP), which finally promote tumor cell 
survival and proliferation, and more extensive bone destruction by osteoclasts 
[4,76]. Thus, the development of lytic bone metastasis relies on an exquisite 
interplay between tumor and stromal cells, which promotes osteoclast-mediated 
bone destruction and increase tumor growth in bone.  
 
1.2.1.2 Cancer stem cells 
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Stem cells are defined by their ability to self-renewal and to give rise to several 
differentiated cells for one specific organ. Similarly, CSC are a subpopulation of 
cells within the heterogeneous population of the tumor [77], which possess self-
renewal and multilineage differentiation potential. It is thought that CSC are 
involved in various phases of tumor progression, from initiation to 
tumorigenesis [78], metastasis promotion [79-81], and resistance to chemo- or 
radiotherapy [82-84]. 
Advocates of the CSC model (also known as the hierarchy model) depict that 
tumors are hierarchically organized and maintained by CSC [85]. This small but 
distinct population of quiescent uncommitted cells can be isolated from the 
tumor mass for their ability to grow and proliferate in anchorage-independent 
conditions forming floating colonies, the so-called “spheres” (Figure 1.3) 
[86,87]. CSC have been successfully isolated from hematological malignancies 
[88,89], and from different types of solid tumors [90,91], including sarcomas 
[92-94], from both immortalized cell lines [93,95] and tissue specimens   
[92,96,97].  
Recent findings have elucidated that CSC differ from the respective native cells 
not only for the peculiar ability to grow as floating colonies, but also for 
morphological and stemness features, and for lysosomal acidity [92,93], which 
probably affect the energy metabolism. 
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Figure 1.3 CSC model. CSC can be isolated from differentiated tumor cells by using the 
sphere-forming assay. A progenitor tumor cells is able to growth in conditions of anchorage-
independence to form CSC with characteristics of stemness, self-renewal, tumor-propagating 
capacity in vivo, and metastasis formation. 
 
The classical model of clonal selection of metastasis asserts that genetic 
mutation attained in the late steps of the tumorigenic process provide a selective 
advantage for metastasis formation. Nevertheless, recent findings have 
elucidated that the metastatic process is also supported by genetic mutations 
acquired in the initial stages of tumor development [98]. Accordingly, a genomic 
approach can highlight the molecular signature that predicts poor prognosis in 
cancer patients. In particular, recent functional genomic analyses have 
highlighted the cellular and molecular mechanisms that mediate the formation of 
tissue-specific metastases [99-101], providing evidence of the presence of a 
small subset of cancer cells within the heterogeneous mass of breast tumor cells 
that is already programmed to preferentially metastasize to specific organs 
[102]. Hence, tumor therapy should be directed at eliminating these tumor-
initiating cells that are primarily responsible for resistance to conventional 
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approaches.  
 
1.3 Metabolic reprogramming in the tumor microenvironment 
Metabolism of cancer cells is different from that of normal cells. Cancer cells 
demands increased energy in form of ATP to support abnormal proliferation and 
macromolecular biosynthesis. In addition, the survival of migrating tumor cells 
outside the primary tumor niche requires adaptation of metabolism to several 
microenvironmental conditions. 
Tumors are highly heterogeneous in all phenotypic features, including 
metabolism. The metabolic profile of tumor cells is controlled by multiple 
molecular mechanisms, including intrinsic genetic mutations and external 
response to tumor microenvironment [103]. Many oncogenic and tumor 
suppressor signaling pathways driving tumorigenesis are key regulators of 
metabolic networks [104], suggesting a tight link between metabolic alterations 
and tumor progression. 
Most tumors and wounds are subjected to low oxygen tension [105], especially 
in the bone microenvironment [106,107]. Hypoxia selects cells to undergo the 
“glycolytic switch”, a fundamental metabolic adaptation by which glycolysis is 
uncoupled from mitochondrial respiration and becomes the main supplier of 
cellular ATP [108]. Although tumor hypoxia can be transient, pioneer studies 
have highlighted that some tumor cells rely on glycolysis even in the presence of 
normal oxygen levels [109]. This is an apparent paradox, considering that 
glycolysis is far less efficient than OXPHOS in producing energy. In fact, the 
catabolism of glucose provide only 2 ATP molecules for each glucose that enters 
in the glycolytic pathway, whereas mitochondrial respiration provides 38 ATP 
molecules. Persistence of aerobic glycolysis is a feature of cancer cells and a 
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hallmark of advanced cancer, and involves stable genetic and epigenetic 
alterations of several oncogenes and tumor-suppressor genes that are still under 
investigation [108]. This phenomenon was first described by Otto Heinrich 
Warburg [110], and is referred as Warburg effect. Aerobic glycolysis is 
characterized by an increased glucose uptake and a large production of 
extracellular lactate and H+ in the tumor microenvironment, which causes a 
decrease of extracellular pH to levels lower that in normal cells [111]. The 
Warburg effect has significant medical application, as high aerobic glycolysis 
has been clinically proven in many malignant tumors. Strong evidence has 
indicated that the glycolytic phenotype confers significant growth advantage to 
cancer cells [112]. In clinical practice, glucose uptake by tumor cells is 
commonly visualized with positron emission tomography (PET) using a 
radiolabelled analogue of glucose (18F-fluorodeoxyglucose).  
Recent studies have shown that the Warburg effect is also activated in stromal 
cells of tumor microenvironment. In particular, cancer-associated fibroblasts 
(CAF) [113,114], that originate from MSC [115], produce energy-rich 
metabolites that can fuel tumor cell metabolism. Cancer cells are able to uptake 
energy-rich metabolites, such as ketones and lactate [116], and use them in the 
TCA cycle and in the mitochondrial metabolism. This phenomenon is known as 
the reverse Warburg effect [117]. This role of tumor-associated stromal cells as 
tumor feeders has been reported in different types of cancer, including human 
breast [116,118] and prostate carcinoma [119], osteosarcoma [120], and head 
and neck cancer [121].  
 
1.3.1 Lactate as metabolic fuel in cancer: the metabolic symbiosis of tumor 
microenvironment  
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Tumor cells uptake more glucose that normal cells, and mainly process it 
through aerobic or anaerobic glycolysis. The increased glycolytic flux is 
associated with a high lactate production rate in malignant cells. In fact, the 
oxidation of glucose through glycolysis produces high levels of pyruvate, 
NADH and protons. Pyruvate, in turn, can be converted to lactate, the end 
product of glycolysis, in malignant, rapidly growing cells. Lactate production 
and excretion by malignant cells in solid tumors leads to a substantial 
accumulation of this metabolite in the tumor microenvironment [122]. Lactate, 
once considered a waste product of glycolysis, has recently emerged as a critical 
regulator of cancer development and a prominent metabolite that fuels the 
oxidative metabolism of oxygenated cells [123,124]. Lactate accumulation in 
human tumors is a predictor of poor prognosis, associated with metastasis, 
tumor recurrence, and patient survival [125-127].  
Lactate metabolism is regulated by several factors, including lactate 
dehydrogenase (LDH) activity, the expression of monocarboxylate transporters 
(MCT) and the oxidative capacity of tissues. The use of lactate as an energy 
source requires, aside to its conversion to pyruvate and back, the transport of 
lactate across the plasma membrane through MCT. MCT proteins mediate the 
exchange of lactate between cells of tumor microenvironment, with MCT4 that 
facilitates lactate export, and MCT1 that promotes lactate uptake [128] (see 
below). Lactate exchange in the tumor microenvironment could fuel the 
oxidative metabolism of tumor cells [123], thereby creating a metabolic 
symbiosis between glycolytic and oxidative cells. In fact, as a result of the 
reverse Warburg effect, mesenchymal cells and CAF of tumor 
microenvironment secrete high levels of lactate, which can be uptaken by 
oxidative tumor cells to support their grow [123]. Once entered into the 
cytoplasm, lactate fuels the TCA cycle and mitochondrial respiration, providing 
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energy for the proliferation of oxidative cells. However, in the cancer 
microenvironment, lactate can be uptaken not only by oxidative tumor cells, but 
also by tumor supporting stroma, like vascular endothelial cells. Recent studies 
have elucidated that in endothelial cells lactate acts both as a signaling molecule 
and as a metabolic intermediate that stimulates endothelial cell migration, tube 
formation, and tumor angiogenesis [128-130]. Lactate can therefore act as an 
energy-transfer molecule in the tumor microenvironment, thereby fueling 
several energy-consuming processes in both tumor and tumor-associated stromal 
cells. 
 
1.3.2 Monocarboxylate transporters as lactate shuttles in cancer  
The transport of monocarboxylates, such as lactate, pyruvate and ketone bodies 
(acetoacetate and D-b-hydroxybutyrate) across the plasma membrane is crucial 
for several metabolic pathways, and is mediated by MCT [131,132]. Between 
these substrates, L-lactate is quantitatively by far the most important substrate in 
cancer metabolism. At physiological pH, lactate is more than 99% dissociated 
into protons and lactate anions. Since it is lactic acid rather than lactate that is 
produced and used in cell metabolism, the capacity of MCT to transport a proton 
with lactate is convenient for its metabolic roles.  
MCT are encoded by the solute carrier (SLC)16 family, which is composed by 
14 members. MCT1 (SLC16A1), MCT4 (SLC16A3), MCT2 (SLC16A7) and 
MCT3 (SLC16A8) facilitate the proton-linked transport of monocarboxylates in 
and out of cells. MCT10 (SLC16A10), also known as T-Type amino acid 
transported 1 (TAT1) is an aromatic amino acid transporter, and MCT8 
(SLC16A2) is a thyroid hormone transporter [133].  
The MCT are membrane proteins spanning the entirety of plasma membrane. 
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They are predicted to have 12 transmembrane domains, with the N- and C-
terminal domains facing the cytosolic side of the membrane and a large 
intracellular loop between the domains 6 and 7. The MCT proteins present 
significant sequence identity in the 12 transmembrane domains, but differ 
mostly in the N- and C-terminal and in the loop sequences [133]. MCT proteins 
require ancillary proteins to be stably expressed at the plasma membrane. The 
ancillary proteins are single-membrane pass glycoproteins with extracellular 
immunoglobulin domains. MCT1, MCT3 and MCT4 associate with the 
chaperone basigin, also known as CD147, EMMPRIN or OX-47, whereas 
MCT2 preferentially associated with the chaperone embigin, also known as 
gp70 [134-136].  
MCT facilitate both influx and efflux of monocarboxylates. The direction of net 
transport is determined by the concentration gradients of protons and 
monocarboxylate across the plasma membrane, and by the affinity for 
monocarboxylates between MCT proteins. The affinity for lactate and other 
monocarboxylates such as pyruvate between MCT is reflected by the Michealis 
Menten constant (Km) value. MCT1 and MCT2 present low Km (high affinity) 
for lactate (3-6 mM for MCT1, 0.5-1 mM for MCT2), suggesting their 
predominant role in the regulation of lactate uptake, whereas the low-affinity 
(high Km) of MCT4 for lactate (25-30 mM) indicates its role in the export of 
intracellular produced lactate.  
The MCT proteins present different patterns of expression in organs and tissues. 
MCT1 is the most widely expressed MCT. It is involved in lactate uptake in the 
cardiac tissue, liver, skeletal muscle and red blood cells. MCT2 and MCT3 have 
a more restricted expression pattern. MCT2 is primarily expressed in liver, 
kidney and neurons in the brain, and in particular it plays key roles in neurons at 
the postsynaptic complex. MCT3 is expressed at the basolateral retinal pigment 
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epithelium and choroid plexus epithelia [137]. MCT4 expression is primary 
limited in highly glycolytic cells, such as white muscle fibers, and is upregulated 
in hypoxic conditions [138].   
MCT1 and MCT4 are the most important lactate shuttles in tumor cells and 
represent promising targets for therapy. As mentioned above, several authors 
have elucidated that lactate exchange in tumors acts as a prominent fuel for the 
oxidative cells of tumor microenvironment, and MCT as crucial component of 
the metabolic symbiosis. In the tumor microenvironment, both oxidative tumor 
cells and endothelial cells close to tumor blood vessels can uptake lactate 
released by glycolytic cells [123,129], and used as main source of metabolic fuel 
by oxidative cancer cells [123]. Glycolysis-derived lactate is released in the 
extracellular microenvironment through the low-affinity lactate shuttle MCT4, 
whereas the exogenous lactate is uptaken by oxidative tumor cells through the 
high-affinity lactate shuttle MCT1. Lisanti and colleagues have provided 
evidence that cancer-associated fibroblasts can undergo aerobic glycolysis to 
support proliferation and metastasis of oxidative cancer cells with the released 
lactate and ketones [116,139]. Another study has reported that lactate can also 
enter tumor-associated endothelial cells through MCT1 [129], demonstrating 
that lactate not only supports the survival of serum-starved endothelial cells, but, 
more interestingly, dictate the pro-angiogenic signaling pathways that drive 
endothelial cell migration and tube formation. More recently, we have reported 
that reactive MSC in osteosarcoma increases lactate production as a result of the 
oxidative stress induced by adjacent tumor cells. Reactive MSC express high 
levels of MCT4 and release energy-rich metabolites that fuel the mitochondrial 
metabolism and the migratory ability of MCT-1 expressing osteosarcoma cells 
[120].  
This evidence supports that altered microenvironmental conditions promote 
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metabolic reprogramming of cancer cells and their stroma, thereby suggesting 
that the impairment of metabolic symbiosis of tumor microenvironment is a 
target for cancer therapy. 
 
1.4 Bone tumor microenvironment as a target of cancer therapy  
Current knowledge suggests that the strict interplay between tumor and stromal 
cells in the bone microenvironment promotes tumor progression and metastasis, 
not only through the paracrine secretion of cytokines and proteic factors, but 
also via intermediate metabolites, which contribute to the metabolic 
reprogramming of tumor microenvironment. Such metabolic reprogramming is a 
common feature of both tumor and stromal cells, which function symbiotically. 
Stroma and bone resident cells are induced by cytokines produced by tumor 
cells, and, in turn, stromal and bone resident cells promote tumor progression 
and metastasis through the release of bone matrix-stored growth factors and 
chemokines. Moreover, stromal cells directly fuel tumor cells by exporting 
lactate and energy-rich metabolites through MCT shuttles, which are 
metabolized by adjacent tumor cells. As a consequence, alteration of the 
metabolic symbiosis can dramatically impair tumor growth.  
Genetic knockdown studies and the synthesis of several small-molecule 
inhibitors of MCT shuttles have confirmed the potential relevance of targeting 
lactate transporters in cancer therapeutics. Sonveaux and colleagues have 
demonstrated that the inhibition of MCT1 through the small molecule alpha-
cyano-4-hydroxy-cinnamate (CHC) [123] can shift the metabolism of the 
lactate-consuming oxidative cancer cells towards the glucose metabolism, 
thereby reducing the amount of glucose available for hypoxic tumor cells and 
impairing their survival. On the other hand, inhibition of MCT4 can potentially 
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target hypoxic cancer cells and promote their death by intracellular lactic acid 
accumulation. Other authors have shown that in tumor-associated endothelial 
cells, knockdown of the MCT1 and MCT4 shuttles determines a dramatic 
inhibition of angiogenesis mediated by endothelial cells, by reducing lactate 
uptake and extracellular lactate availability, respectively [129]. More 
convincingly, the inhibition of MCT1 with AR-C155858, a highly selective and 
potent MCT1/MCT2 inhibitor, blocks the proliferation and tumorigenicity of 
tumor-activated fibroblasts [140]. Furthermore, a second-generation 
MCT1/MCT2 inhibitor, AZD3965, is in Phase I clinical trials for patients with 
advanced solid tumors, prostate cancer, gastric cancer and diffuse large B cell 
lymphoma (Cancer Research UK. A Phase I Trial of AZD3965 in Patients With 
Advanced Cancer. https://clinicaltrials.gov/ct2/show/NCT01791595).  
The exquisite metabolic symbiosis of the tumor microenvironment supports the 
development of MCT inhibition strategies. There is a real hope that agents that 
target lactate metabolism and transport between cells of the tumor 
microenvironment will substantially contribute to anti-cancer therapy. However, 
nothing is currently known about the role of lactate metabolism in lytic bone 
metastasis. To extend such strategies to efficient anti-bone metastasis therapy, a 
better understanding of lactate shuttling in osteolytic metastases is clearly 
needed. 
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2. AIM OF THE STUDY 
 
The aim of this study was to evaluate the influence of the metabolic symbiosis 
between tumor cells and cells of bone microenvironment in lytic bone 
metastases. Osteolytic metastases are a devastating event for many patients with 
advanced breast cancer, often leading to a significantly decreased quality of life. 
Despite progress in understanding the molecular biology of metastatic breast 
tumor cells, to date there are no specific therapies for metastatic bone disease. 
Current treatments are mainly palliative. Hence, it is pivotal to gain a more in-
depth knowledge on the metabolic regulation of lytic bone metastases, and the 
interplay between the cellular elements of the metastatic microenvironment. 
Consequently, during my doctoral training I focused on the previously 
mentioned issues.  
In lytic bone metastases from breast cancer, tumor cells harness the osteolytic 
activity of osteoclasts to promote bone resorption and remodeling, thereby 
creating a metastatic niche. Osteoclasts and tumor cells support each other 
through a vicious cycle in which tumor cells produce cytokines that support 
osteoclast formation and activation, and osteoclast activity promotes the release 
of bone-embedded growth factors, which, in turn, promote tumor cell 
proliferation. However, we postulated that this mechanism is not exhaustive to 
explain the complex microenvironment of bone metastases, because high-energy 
metabolites produced by the peculiar metabolism of tumor cells can be even 
more relevant in this context. We supposed that in the tumor microenvironment, 
lactate produced by the glycolytic metabolism of breast tumor cells could be 
uptaken by osteoclasts to promote its oxidative metabolism, and support the 
energy-consuming process of bone destruction, thereby promoting osteolytic 
diseases. To verify this hypothesis of the metabolic symbiosis of tumor 
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microenvironment, during my doctoral training I first investigated the basal 
metabolism of human osteoclasts during osteoclastogenesis, then analyzed the 
metabolic adaptations underling the activation of mature osteoclasts to 
resorption, and subsequently analyzed the role of lactate in the interplay between 
tumor and bone-resident cells.  
The microenvironment of osteolytic metastasis is heterogeneous, and involves 
many different actors, among which the most important are osteotropic tumor 
cells, cancer stem cells (CSC) and bone-resident cells. The contribution of CSC 
to metastatic diseases is currently an important focus of investigation. With the 
aim to lay the groundwork for analyses on the gene expression profile of CSC 
and native cells, during my doctoral training I also focused on the identification 
and validation of housekeeping genes for gene expression analysis of CSC and 
native tumor cells from breast and renal carcinoma, two osteotropic tumors, and 
sarcomas, primary tumors of bone.  
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3. MATERIALS AND METHODS 
 
3.1 Cell culture  
3.1.1 Human osteoclast cultures 
Primary cultures of osteoclasts were obtained from monocytic precursors 
isolated from fresh buffy coats obtained from n.=15 different healthy donors 
(AVIS, Bologna, Italy; Saint-Luc University Hospital, Brussels, Belgium), as 
previously described [19]. Briefly, peripheral blood mononuclear cells (PBMC) 
were layered over Hystopaque (GE Healthcare) and seeded on tissue-culture 
glass or plasticware (3,000,000 cells/cm2) in Dulbecco's Modified Eagle 
Medium (DMEM; Sigma) supplemented with 25 mM glucose (Merck), 10% 
heat-inactivated fetal bovine serum (FBS; Celbio), plus 20 U/mL penicillin, 100 
mg/mL streptomycin (Euroclone), and incubated at 37 °C in a humidified 5% 
CO2 atmosphere. All experiments were performed in pyruvate- and glutamine-
free media buffered at pH 7.4 (3.7 g/liter NaHCO3) (complete DMEM), unless 
stated otherwise. After 2 hours, medium was discarded and replaced with 
complete DMEM added with RANKL [50 ng/mL] and M-CSF [10 ng/mL] 
(Peprotech) (pro-osteoclastogenic medium), or with complete DMEM without 
pro-osteoclastogenic factors (control medium), depending on the experimental 
conditions. In order to verify osteoclast differentiation, after 5 to 7 days of cell 
culture, cells were analyzed for tartrate-resistant acid phosphatase (TRAP) 
activity by cytochemistry (Acid Phosphatase Leukocyte assay, Sigma) and 
stained with Hoechst 33258. Only TRAP+ cells with 3 or more nuclei were 
considered as osteoclasts. 
 
3.1.2 Growth condition and propagation of adherent tumor cell lines 
Rhabdomyosarcoma cell line (RD), osteosarcoma cell lines (MG-63, HOS, 
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Saos-2), Ewing’s sarcoma cell line (A-673), breast carcinoma cell line (MDA-
MB-231), renal carcinoma cell line (ACHN), and bone marrow derived MSC 
were purchased from American Type Culture Collection (ATCC). MDA-MB-
231 bone metastasis cell line was kindly provided by Nadia Rucci (University of 
L’Aquila, Italy) [141]. MSC were maintained in alpha-Modified Eagle’s 
Medium (α-MEM, Sigma), supplemented with 10% heat-inactivated FBS 
(Sigma), plus 20 U/mL penicillin (Gibco), 100 mg/mL streptomycin (Gibco). All 
the other cell lines were maintained in Iscove’s modified Dulbecco’s medium 
(IMDM, Gibco), plus 20 U/mL penicillin, 100 mg/mL streptomycin, and 10% 
heat-inactivated FBS (complete IMDM). All the cell lines were grown under 
controlled atmosphere in the presence of 5% CO2 at 37 °C. Complete medium 
were prepared by filtering the mixture using a 0.2 μm filter. Cells were grown in 
plastic cell culture flasks until 90% confluence. The medium was removed and 
washed once with PBS buffer, and 10% trypsin solution was added for 5 
minutes. Fresh medium was added to block the protease action, cells were 
collected into a plastic tube and centrifuged for 5 min at 1000 rpm. The pellet 
was resuspended in fresh medium and placed in a new plastic flask.  
A human primary ES culture (ES4540) was also used, previously obtained from 
a fresh biopsy of human ES, and characterized as previously described [92]. The 
ES4540 sample was collected after a signed informed consent and following the 
approval of the institutional ethical committee (0033626, 9 Nov 2011), 
according to the Declaration of Helsinki. Briefly, tissue samples were subjected 
to mechanical mincing, followed by enzymatic digestion, to obtain single cells 
that were seeded in complete IMDM until the formation of a monolayer.   
 
3.1.3 Cancer stem cells cultures  
CSC cells were obtained as previously described [92]. Briefly, RD, MG-63, 
HOS, Saos-2, A-673, MDA-MB-231, ACHN, and ES4540 cultures were 
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maintained in anchorage-independent conditions in DMEM:F12 medium with 
progesteron (20 nM), putrescin (10 mg/mL), sodium selenite (30 nM), apo-
transferrin (100 μg/mL), and insulin (25 μg/mL) (Sigma-Aldrich, St. Louis, MO) 
in low-attachment flasks (Nunc, Penfield, NY) (sphere-forming assay). We 
obtained the CSC culture by maintaining the spheroid in anchorage-independent 
conditions in specific cell media, adding the growth factors EGF and bFGF 
every 3-4 days (twice at week). Fresh human EGF (20 ng/mL) and bFGF (10 
ng/mL) (PeproTech, Rocky Hill, NJ) were added twice a week until cells started 
to grow as floating aggregates (spheres). Spheroid cultures were amplified by 
treating the primary CSC culture with trypsin, followed by gentle mechanical 
dissociation, and by re-plating single-cell suspension to obtain the second 
spheroid culture. Viability was verified by erythrosine staining. The percentage 
of dead cells was low (10-15% of dead cells). Only those cultures that were able 
to form spheres and that expressed stem cell-related markers were considered.  
 
3.2 Metabolic assays  
3.2.1 Glucose consumption and lactate production 
Glucose consumption and lactate production were measured by analysing the 
metabolite content of deproteinized cell culture supernatants. PBMC were 
seeded as described above on 96-well plates in control media or pro-
osteoclastogenic media and cultured until multinucleated TRAP+ cells were 
formed (around 7 days). To analyze osteoclast basal metabolism, media was then 
changed with fresh control media or pro-osteoclastogenic, respectively, and after 
additional 5 days, the supernatant was collected. To analyze the effect of lactate 
on osteoclast metabolism, media were then changed with fresh complete 
medium containg 10 mM sodium lactate (Sigma), or control media, and after 
additional 7 days the supernatant was collected. Metabolite concentrations were 
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quantified using specific enzymatic assays on CMA600 analyzer (CMA 
Microdialysis AB). Glucose consumption and lactate production were 
normalized on total protein content using the Bradford protein assay (Bio-Rad). 
Results were representative of 3 independent experiments, with 5 technical 
replicates for each condition. 
 
3.2.2 Oxygen consumption and extracellular acidification measurement 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
were determined using a Seahorse XF96 extracellular Flux analyzer with a 
mitostress kit (Seahorse Biosciences). To analyze osteoclast basal metabolism, 
PBMC were seeded on XF96 cell culture plate in control media or pro-
osteoclastogenic media, and incubated from 2 to 14 days. To analyze the effect 
of lactate on osteoclast metabolism, after osteoclast formation (7 days) media 
was then changed with fresh complete medium containg 10 mM sodium lactate, 
or control media, and after additional 7 days cells were analyzed. Culture media 
were changed with base media (unbuffered DMEM supplemented with 25 mM 
glucose) 1 hour before. Selective inhibitors were injected during the 
measurements to achieve final concentrations of oligomycin [2 μM], Carbonyl 
cyanide 4-trifluoromethoxy phenylhydrazone FCCP [0.9 μM], rotenone [1μM] 
antimycin A [1μM], and 2-deoxy-glucose [100 mM]. Mitochondrial OCR 
(mtOCR) was assayed by injecting rotenone and antimycin to acutely inhibit 
mitochondrial-driven oxygen consumption. mtOCR was calculated by 
subtracting non-mitochondrial OCR from total OCR levels. ATP coupling were 
calculated by subtracting total OCR from oligomycin readings, which uncouples 
ATP synthesis from oxygen consumption. Data were normalized for total protein 
content using the Bradford protein assay. Results are representative of 3 
independent experiments with 7 technical replicates each.  
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3.2.3 ATP assay 
PBMC were seeded on 12-well plates and maintained in pro-osteoclastogenic 
media or control media until multinucleated TRAP+ cells were obtained (around 
7 days). Two hours before the assay, media were changed with fresh pro-
osteoclastogenic media or control media. Cells were washed and lysed by using 
boiling ATP lysis buffer [0.1 M Tris(hydroxymethyl) aminomethane (Tris base) 
(Sigma) and 2 mM EDTA adjusted to pH 7.75 with acetic acid (Sigma)]. Cell 
lysates were added to a reaction mixture containing luciferase and luciferine 
(ATP Determination Kit, Molecular Probes) for bioluminescence quantification 
by using Infinite® 200 PRO plate reader (Tecan). ATP level was normalized 
with total protein content (Bradford protein assay). Results were representative 
of 3 independent experiments, with 4 technical replicates each. 
 
3.2.4 14C-Lactate uptake assay 
PBMC were seeded on flat-bottom 24-well plates, and maintained in pro-
osteoclastogenic media until osteoclast differentiation was obtained. When 
multinucleated TRAP+ cells were formed (around 7 days), the culture medium 
was replaced by pro-osteoclastogenic media containing 10 mM sodium lactate, 
and incubated overnight for metabolic adaptation. Cells were first rinsed with a 
modified Krebs solution (containing 10 mM L-lactate, without glucose), and 
exposed to increasing concentrations of 14C-L-Lactate (1, 2, 4, 8, 16 μM) or 
control Krebs solution at 37°C for 12 minutes. Cells were then rinsed with ice-
cold D-lactate-containing Krebs solution (10 mM D-lactate, without glucose) 
and lysate with 0.1 M NaOH. Sample aliquots were then incubated in liquid 
scintillation solution (Microscint 40) into a 96-well plate (Optiplate). After a 1 
hour agitation, radioactivity was measured (PerkinElmer Topcount). Cpm values 
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were nomalized per protein amount (Bradford protein assay).  
 
3.3 Resorption assay  
Resorption activity was measured by using the OsteoLyse bone resorption assay 
kit (Lonza). Cells were cultured in pro-osteoclastogenic media until osteoclast 
differentiation (5 to 7 days), and then media was replaced with specific media 
for 72 hours. In particular, we used DMEM medium supplemented with 
penicillin [20 U/mL] and streptomycin [100 mg/mL], 10% FBS, buffered at pH 
7.4 with 3.7 g/liter NaHCO3, plus 20 mM glucose (complete glucose medium), 
or 20 mM galactose (Sigma) (complete galactose medium), or with complete 
galactose medium supplemented with rotenone (10 nM; Sigma). Supernatants 
were collected after 10 days and the fraction of collagen Type I degradation 
quantified by the emission of Europium-labelled collagen fragments via time 
resolved fluorescence (Infinite® 200 PRO, Tecan, exc. 340 nm, ems. 615 nm). 
 
3.4 SDS-PAGE and immunoblotting  
PBMC were seeded on cell culture dishes, and maintained in pro-
osteoclastogenic media or control media until osteoclast differentiation was 
obtained. When multinucleated TRAP+ cells were formed (around 7 days), cells 
were lysed with RIPA buffer [Tris pH 7.6 50 mM, NaCl 150 mM, Triton-X 100 
5%, sodium deoxycholate 0.25%, EGTA pH 8 1 mM, NaF 1 mM] (Sigma) 
containing protease and phosphatase inhibitor cocktails (Roche). Protein lysates 
were subjected to reducing SDS-PAGE on polyacrylamide gel and transferred to 
nitrocellulose membrane (Thermo Fisher Scientific). Membranes were stained 
with Ponceau red (Sigma) to confirm equal amount protein loading. Blots were 
probed with MitoProﬁle Total OxPhos human antibody Cocktail (1:300; 
ab110411, Abcam), with MCT1 (1:1000, Chemicon, AB3538P), with ACTB 
 43
(1:1000, Cell signalling, 4970) and with anti-Heat Shock Protein 60 kDa 
(HSP60, 1:2000; HPA001523, Sigma), followed with horseradish peroxidase-
conjugated anti-mouse and anti-rabbit (GE Healthcare). To detect HSP60 and 
ACTB within the same blot, nitrocellulose membranes were stripped with 
Restore Western Blot Stripping buffer (Thermo Fisher Scientiﬁc), and reprobed. 
The reaction was revealed by a chemiluminescence substrate (ECL Western 
Blotting Detection Reagents, GE Healthcare). The signal from each band was 
quantiﬁed by dedicated software for densitometric evaluation (VisionWorksLS 
Analysis Software, Biospectrum, UVP). Results are representative of 4 
independent experiments.   
 
3.5 Microscopy analyses 
3.5.1 Immunofluorescence analyses 
Immunofluorescence assays were performed on PBMC cultured on glass 
coverslips with pro-osteoclastogenic media or control media. Cells were fixed in 
2% paraformaldehyde. Permeabilization was performed with 0.5% Triton X-100 
in HEPES and blocked with 1% BSA. We used anti-mitochondria MAb against 
the surface of intact mitochondria  (clone 113-1, MAB1273, Merck Millipore, 
1:50). As a secondary antibody we used anti-mouse or anti-rabbit antibodies 
Alexa Fluor 488 nm (Life Technologies). Nuclei were stained with Hoechst 
33258. Mitochondrial mass index was quantified as the ratio of the area with a 
fluorescent signal with the total area of the single cell by using NIS Element 
image software BR4.00.00 (Nikon). 28 different random cells were counted. 
Mitochondria networks were observed by confocal microscope (Nikon TI-E). 
 
3.5.2 Immunohistochemistry 
Paraffin sections of giant-cell tumor of bone were stained with MCT1 antibody. 
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Sections were dewaxed, rehydrated through graded ethanol series, and antigen 
retrieval was performed with 10 mM citrate buffer, pH 6.0 for about 10 minutes 
using a microwave. The cooled sections were blocked with 3% hydrogen 
peroxide and next incubated with 5% BSA for 1 hour, followed by overnight 
incubation with anti-MCT1 antibody (HPA003324, 1:100, Sigma) at 4°C. 
Biotinylated secondary antibodies followed by streptavidin-horseradish 
peroxidase conjugated were from Dako. Immunoreactivity was revealed with the 
DAB solution (Dako). Sections were counterstained with hematoxylin. 
 
3.5.3 Electron microscopy  
CD14+ cells were isolated from the mononuclear cell population obtained from 
buffy coats with the method described above, and according to a protocol 
previously defined [142]. Briefly, we used an immunomagnetic cell separation 
technique (MACS, Miltenyi Biotech). Cells were washed with MACS buffer 
(PBS pH 7.2 supplemented with 0.5 % bovine serum albumin and 2 mM 
ethylene diamine tetracetic acid), and clumps were removed by passing cells 
through a 30 mm pre-ﬁlter. Cells were then centrifuged at 400 g. The cell pellet 
was resuspended in MACS buffer and counted. 107 cells were mixed with anti-
CD14 MACS antibody-coated microbeads, and incubated at room temperature. 
The cell suspension was applied to an LS-positive selection column previously 
washed with MACS buffer, and placed in a magnetic separation unit. The 
column was rinsed and removed from the magnetic separation unit, and positive 
bound cells were ﬂushed. The collected cell population was then used for 
ultrastructure evaluation. Pellet of CD14+ cells from PBMC and glass-adherent 
osteoclasts were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 
7.4, for 1 hour, postfixed with 1% osmium tetroxide (Electron Microscopy 
Science), dehydrated in a graded series of ethanol, and embedded in Epon 
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(Electron Microscopy Science). The embedded samples were sectioned on 
ultramicrotome (Ultracut E, Richert-Jung, Leica Microsystem). Thin sections 
(90 nm thick) were collected on 300 mesh nickel grids and stained with uranyl 
acetate (Electron Microscopy Science) and lead citrate. Mitochondria were 
observed by using a Zeiss EM 109 apparatus (Zeiss). Images were captured with 
Nikon digital camera Dmx 170 1200F and ACT-1 software. 
 
3.6 Molecular biology procedures 
3.6.1 Total RNA isolation and cDNA synthesis 
Total RNA was extracted from CSC and native cells from all the different 
histotypes included in the study, and from osteoclasts, control cells, MDA-MB-
231, MDA-MB-231 bone met, MSC and osteoblast, by using the NucleoSpin 
RNA II (Macherey-Nagel, Düren, Germany). On-column DNase digestion was 
performed following manufacturer’s instructions. The total RNA purity was 
quantified using a Nanodrop Spectrophotometer (NanoDrop Technologies). 
Total RNA (0.5 μg) were reverse-transcribed into cDNA in 20 μl final volume, 
using MuLV Reverse Transcriptase and RNase inhibitor (Applied Biosystems, 
Foster City, Ca, USA). First-strand cDNA was synthesized using random 
hexamers. For each sample, 3 biological replicates were processed. 
 
3.6.2 qRT-PCR 
qRT-PCR was performed by using a Light Cycler instrument and the Universal 
Probe Library system (Roche Applied Science, Monza, Italy). Probe and primers 
were selected by using a web-based assay design software (ProbeFinder 
https://www.roche-applied-science.com), and were further controlled using 
Oligo Primer Analysis Software. Only primers spanning an exon-exon junction 
and producing a PCR amplificate with length between 70 and 150 base pairs 
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were selected. All the primers designed were analyzed by BLAST to verify their 
specificity (National Center for Biotechnology Information). All cDNA were 
diluted 1:10, and 10 μl were used as template and included in a 20 μl of total 
volume of qRT-PCR reaction. The protocol of ampliﬁcation was: 95°C for 10 
min; 95°C for 10 s, 60°C for 30 s, and 72°C for 1 s for 45 cycles; 40°C for 30 s. 
Each assay included a blank. Table 1 provides a summary of all the 
housekeeping genes (HKG), primer sequences, and probes included in this 
study.  
 
Table 3.1. Candidate HKG genes 
Gene  Full 
name 
Function Accession 
Number 
Primers  Probe 
18S 
rRNA 
18S 
ribosoma
l RNA 
Structural RNA for 
the small 
component of 
eukaryotic 
cytoplasmic riboso
mes. 
X03205.1 F=gcaattattccccatgaac
g 
R=gggacttaatcaacgcaa
gc 
48 
ACTB Actin, 
beta 
Cytoskeletal 
structural protein 
NM_00110
1.2 
F=ccaccgcgagaagatga 
R=ccagaggcgtacaggga
tag 
64 
B2M Beta-2-
microglo
bulin 
Component of the 
class I major 
histocompatibility 
complex (MHC) 
NM_00404
8.2 
F=ttctggcctggaggctatc 
R=tcaggaaatttgactttcca
ttc 
42 
G6PD Glucose-
6-
phosphat
e 
dehydrog
enase 
 
Produces pentose 
sugars for nucleic 
acid synthesis and 
main producer of 
NADPH reducing 
power 
M24470.1|
M24470 
F=gaagggccacatcatctct
g 
R=atctgctccagttccaaag
g 
75 
GAPDH Glyceral
dehyde 
3-
phosphat
e 
Oxidoreductase in 
glycolysis and 
gluconeogenesis 
NM_00204
6.3 
F=agccacatcgctcagaca
c 
R=gcccaatacgaccaaatc
c 
60 
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dehydrog
enase 
GUSB Beta-
glucuron
idase 
Hyrolase that 
degrades 
glycosaminoglycans 
M15182.1|
M15182 
F=cgccctgcctatctgtattc 
R=tccccacagggagtgtgt
ag 
57 
HMBS Hydroxy
methylbi
lane 
synthase 
Third enzyme in the 
heme biosynthetic 
pathway 
NM_00019
0.3 
F=tgtggtgggaaccagctc 
R=tgttgaggtttccccgaat 
26 
HPRT1 Hypoxan
thine 
phosphor
ibosyltra
nsferase 
1 
 
Purine synthesis in 
salvage pathway 
M31642.1|
M31642 
F=tgaccttgatttattttgcata
cc 
R=cgagcaagacgttcagtc
ct 
73 
PGK1 Phospho
glycerate 
kinase 1 
Transferase in 
glycolysis and 
gluconeogenesis 
NM_00029
1.3 
F=ggagaacctccgctttcat 
R=gctggctcggctttaacc 
69 
PPIA Peptidyl
prolyl 
isomeras
e A 
(cyclophi
lin A) 
Isomerase involved 
in the cis-
trans isomerization 
of peptide bonds in 
oligopeptides  
NM_02113
0.3 
F=atgctggacccaacacaa
at 
R=tctttcactttgccaaacac
c 
48 
RPL13a Ribosom
al protein 
L13a 
Structural 
component of the 
large 60S ribosomal 
subunit 
NM_01242
3.3 
F=caagcggatgaacaccaa
c 
R=tgtggggcagcatacctc 
28 
SDHA Succinat
e 
dehydrog
enase 
complex, 
subunit 
A, 
flavoprot
ein (Fp) 
Electron transporter 
in the TCA cycle 
and respiratory 
chain 
NM_00416
8.2 
F=ggacctggttgtctttggtc 
R=ccagcgtttggtttaattgg 
80 
TBP TATA-
binding 
protein  
General RNA 
polymerase II 
transcription factor 
NM_00117
2085.1 
F=ttgggttttccagctaagttc
t 
R=ccaggaaataactctggct
ca 
24 
TUBB Tubulin, 
beta 
Major constituent of 
microtubules 
NM_17801
4.2 
F=ataccttgaggcgagcaa
aa 
64 
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class I R=tcactgatcacctcccaga
ac 
YWHA
Z 
Tyrosine 
3-
monooxy
genase/tr
yptophan 
5-
monooxy
genase 
activatio
n protein 
zeta 
polypepti
de  
Belongs to the 14-
3-3 family of 
protein which 
mediate signal 
transduction 
NM_00340
6.3 
F=ccgttacttggctgaggttg 
R=tgcttgttgtgactgatcga
c 
9 
 
To evaluate MCTs expression by cells of the bone metastatic microenvironment, 
MCT1 (NM_003051.3) and MCT4 (NM_001206952) were analyzed by using 
the following primers: MCT1-F 5’-ggattggtgaccattgtgg-3’, MCT1-R 5’- 
catgtcattgagccgaccta-3’. MCT4-F 5’- gagtttgggatcggctacag-3’, MCT4-R 5’- 
cggttcacgcacacactg-3’. The relative expression of MCT1 and MCT4 were 
normalized by the reference gene ACTB for MDA-MB-231 and MDA-MB-231 
bone met, by TBP for osteoclasts and precursors cells, or by PPIA for MSC and 
osteoblast [143]. Relative expression calculation was performed using the 
ΔΔCt model [144].  
For the evaluation of the expression of stemness markers of CSC, c-Myc 
(NM_002467.4), KLF4 (NM_004235.4), Nanog (NM_0248695.2) and OCT3/4 
(NM_002701.4) were analysed, and the following primers were used: c-Myc-F 
5’-gctgcttagacgctggattt-3’, c-Myc-R 5’-taacgttgaggggcatcg-3’, probe 66; KLF4-
F 5’-ccatctttctccacgttcg-3’, KLF4-R 5’-agtcgcttcatgtgggagag-3’, probe 7;. 
Nanog-F 5’-ATGCCTCACACGGAGACTGT-3’, Nanog-R 5’-
AGGGCTGTCCTGAATAAGCA-3, probe 69; OCT3/4-F 5’-
CTTCGCAAGCCCTCATTTC-3’, OCT3/4-R 5’-
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GAGAAGGCGAAATCCGAAG-3’, probe 60. For the purpose of 
normalization, the relative expression of KLF4, c-Myc, Nanog and OCT3/4 
were normalized by the reference gene ACTB or for the geometric average of 
YWHAZ and GAPDH for CSC and native cells from MG-63, or for the 
geometric average of PPIA and HMBS for CSC and native cells from ACHN 
and MDA-MB-231. The relative expression of the stem cell markers was 
calculated using the ΔΔCt model [144].  
 
3.7 Illumina Genome Analyzer sequencing and data analysis 
A deep sequencing analysis of MG-63, HOS, and Saos-2 OS cell models was 
performed to compare the global transcriptional expression of CSC to the 
respective native cells, in order to select a panel of stable HKG for qRT-PCR 
analysis. Briefly, total RNA was collected from the cell lysate in acid 
guanidinium thiocyanate-phenol-chloroform [145]. The total RNA was 
quantified by Bioanalyzer (Agilent, Santa Clara, CA) following the 
manufacturer's instructions. RIN (RNA Integrity Number) and A260/A280 ratio 
of the prepared total RNA were all 10, and over 1.8, respectively. The library of 
template molecules for high throughput DNA sequencing was converted from 
the total RNA using TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, 
CA), following the manufacturer's protocol. The library was also quantified with 
Bioanalyzer (Agilent), following the manufacturer's instruction. The library (7 
pM) was subjected to cluster amplification on a Single Read Flow Cell v4 with a 
cluster generation instrument (Illumina). Sequencing was performed on a 
Genome Analyzer GAIIx for 70 cycles using Cycle Sequencing v4 regents 
(Illumina). Human genome build 19 (hg19) were downloaded from University 
of California, Santa Cruz genome browser (http://genome.ucsc.edu/). Image 
analysis and base calling were performed using Off-Line Basecaller Software 
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1.6 (Illumina). Reads were aligned using ELAND v2 of CASAVA Software 1.7 
with the sequence data sets. Transcript coverage for every gene locus was 
calculated from the total number passing filter reads that mapped, by ELAND-
RNA, to exons. These analyses were performed using default parameters. The 
data were viewed using Genome Studio Software (Illumina). The advanced 
analysis for quantification with Quantile normalization algorithm was performed 
using Avadis NGS software (version1.5, Strand Scientific Intelligence Inc., San 
Francisco, CA).  
 
3.8 Software for housekeeping gene stability analyses 
3.8.1 NormFinder analysis 
NormFinder program is a VBA applet [146] based on a variance estimation 
approach, which ranks the candidate HKG based on their stability evaluation, 
and assigns a stability value to each candidate gene using a model-based 
approach. In agreement with NormFinder requirements, the Ct values were 
transformed in relative quantity, using the lowest Ct value as calibrator. 
According to the analysis, the lowest stability value was top ranked. We grouped 
all the data in 3 different clusters: 1) all data from CSC of different tumors; 2) 
all data from native cells of different tumors; 3) all data from different tumors 
with CSC and native cells pooled together. For the third group of data, in 
addition to CSC and native cells obtained from all tumors pooled together, we 
also considered CSC and native cells obtained from the single tumor type, from 
sarcoma or from carcinoma.  All results were obtained from 3 sets of replicates. 
 
3.8.2 GeNorm analysis 
GeNorm v. 3.0 [147] available in qbase+ [148] (Biogazelle, Ghent University, 
Belgium, http://www.qbaseplus.com) was used to evaluate the stability of 
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candidate HKG. GeNorm calculates all the possible average pairwise variation 
between the candidate genes and provides a measure of the expression stability 
(M) of each gene. An M-value below 1.5 indicates stable HKG. The candidate 
reference gene with the lowest M value was considered to have the most stable 
expression. GeNorm ranks candidate reference genes on the basis of their 
stability of expression, and performing stepwise exclusion of the gene with the 
highest M-value (the least stable expressed gene), and recalculates M-values for 
the remaining genes. We use also GeNorm to verify if a single HKG is sufficient 
for an adequate normalization. Indeed, GeNorm provides the optimal number of 
reference genes required for accurate normalization. V values below the cut-off 
value 0.15 indicated the optimal number of genes required for data 
normalization. Similarly to the analysis performed with NormFinder, we 
grouped all the data and the results in 3 different clusters. All results were 
obtained from 3 sets of replicates. 
 
3.8.3 Coefficient of variation analysis 
Gene expression stability evaluated by the coefficient of variation (CV) was 
calculated by dividing the standard deviation (SD) of threshold cycles (Ct) by 
the mean Ct value. As in the analysis performed with NormFinder and GeNorm, 
we grouped all the data in 3 different clusters, and the results were obtained 
from 3 sets of replicates. 
 
 3.8.4 Rank aggregation 
The analyses performed by the three described methods showed some 
differences in the stability rank of the HKG. Therefore, we identified the most 
stable genes by considering the lowest value of the mathematic average of the 
NormFinder, geNorm and CV method ranks for every single gene. 
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3.9 Statistical analyses 
Statistical analysis was performed using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com). Due to low number of observations, data were considered 
as not normally distributed, and nonparametric Mann-Whitney U test were used 
to evaluate the differences. The Spearman Rank correlation test was used for the 
correlation analyses. Results were reported as mean ± standard error of mean 
(SEM). Standard deviation (SD) of delta cycle threshold (ΔCt) values was 
calculated as pooled standard deviation (SDpooled). HKG expression variation 
in CSC and native cells was evaluated with the paired Wilcoxon signed-rank 
test. For all the analyses, differences were considered signiﬁcant with a p-values 
≤ 0.05. 
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4. RESULTS 
 
To evaluate the complex interaction between the cells of the bone metastatic 
microenvironment underlying the formation and activation of lytic lesions, we 
focused on the study of metabolic adaptation that occurs in the bone 
microenvironment. The result chapter is divided in three sections. In the first 
section I characterized the basal metabolism of human osteoclast cells, the main 
actors of bone resorption in osteolytic metastases, during osteoclast formation 
and activity. In the second section I analyzed the role of lactate, an energy-rich 
metabolite produced by the glycolytic metabolism of metastatic breast 
carcinoma cells, on osteoclast cells. In the third section, with the aim to lay the 
groundwork to future analyses on the role of CSC in bone metastases, I 
validated the most stable housekeeping genes for the comparison CSC with 
respect to native adherent tumor cells (this section is modified from Lemma S. et al, 
2016. PLoS ONE 11(2): e0149481).  
 
Section 1: Energy metabolism is finely tuned during osteoclast formation 
and function 
 
4.1.1 Mitochondrial mass increases along with the osteoclast differentiation 
process 
Human osteoclasts were obtained from PBMC treated with the pro-
osteoclastogenic media containing RANKL and M-CSF. At 2 days, 
undifferentiated mononuclear precursors were observed that, after 7 days of 
culture, fused together to form TRAP+ multinucleated osteoclasts. The number 
of fully differentiated osteoclasts was maintained until 14 days of cell culture 
(Fig. 4.1A).  
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In mature osteoclasts, the mitochondrial mass was markedly and significantly 
increased with respect of precursor cells at 2 days of culture (Fig 4.1B-C 
***p<0.0001). We also found a positive correlation between mitochondrial mass 
and both the number of nuclei and the cell size (Fig. 4.1D, R2=0.9122, *p = 
0.0178).  
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Figure 4.1. Human osteoclasts display an increased mitochondrial mass. (A) TRAP and 
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nuclei staining of osteoclast cultures at 2, 7 and 14 days (white arrows show multinucleated 
TRAP+ cells); (B) Representative images of immunofluorescence with anti-mitochondria 
antibody (right panel) of osteoclast precursors at 2 days of culture (upper panel) and mature 
osteoclasts at 7 days of culture (bottom panel). The osteoclast phenotype of the observed cells 
were confirmed by TRAP staining and multinuclearity (left panel). Original magnification, 
40x. Scale bar 20 μm; (C) Mitochondrial mass index during osteoclastogenesis (***p<0.0001, 
n=28); (D) Mitochondrial mass is directly correlated with the number of nuclei for cell 
(R2=0.9122, n=9) and with osteoclast size (n=15). Only cells with 3 or more nuclei were 
considered in the analyses. 
 
Then, mitochondria were examined at different osteoclast differentiation phases 
by ultrastructural analysis. Osteoclasts derive largely from CD14-positive cells, 
therefore, to obtain a pure population of osteoclast precursors, we used CD14-
positive monocyte isolated from PBMC as model of osteoclast precursor cells. 
Both CD14-positive cells and osteoclast were characterized by a high number of 
mitochondria in the cytosol. Osteoclasts showed large mitochondria (Fig. 4.2, 
left panels), with a complex organization of cristal membranes (Fig.4.2, right 
panels) respect to CD14-positive precursors. 
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Figure 4.2. Ultrastructural analysis of mitochondria. Representative images from 
monocytic precursors (CD14-positive cells) isolated from PBMC (upper panels) and mature 
osteoclasts (7 days, lower panels). Scale bars: 1.5-2 μm on the left, 0.2 μm on the right, 100 
nm for magnification.  
 
The overall morphology of the entire mitochondrial network of osteoclast was 
observed by confocal microscopy. In human osteoclasts, mitochondria appeared 
as a reticulum clustered in the perinuclear region (Fig. 4.3A) that extended 
outward into the peripheral basal domain of the cell, where appeared to be 
elaborately interconnected and ramified (Fig 4.3B). The mitochondrial reticulum 
was made up of tubular structures that localized perinuclear in the apical domain 
of the cells and branch out to the lower side of the cells, where it organized as 
elongated tubular structure close to the basal domain of the osteoclast (Fig. 4.4).  
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Figure 4.3. Mitochondria of mature osteoclast are organized in tubular structure. (A) 
Osteoclasts were stained with an anti-mitochondria antibody, and analyzed by confocal 
microscopy. The presence of mature osteoclasts was revealed by positivity to TRAP staining 
and the presence of more than 3 nuclei. Mitochondria clusters in the perinuclear region. (B) 
Detail of the tubular structure organization of mitochondria in osteoclasts.  
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Figure 4.4. Mitochondria network in mature osteoclast. Note that tubular structure of 
mitochondria localized in the basal domain of osteoclast. 
 
4.1.2 Mitochondrial energy metabolism increases during osteoclast 
differentiationSince mitochondrial biogenesis is usually associated with 
increased OxPhos, we analyzed the expression of OxPhos complex subunits, 
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total intracellular ATP pool, and the respiration rate in osteoclasts in respect to 
control cells. As control cells we used mononuclear precursors cultured for the 
same number of days and not treated with growth factors. Western blot analyses 
revealed that osteoclasts express significantly higher levels of complexes I, II, 
III and V with respect to control cells (Fig 4.5A-B), and produced higher levels 
of intracellular ATP with respect to control cells (Fig 4.5C).  
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Figure 4.5. Expression of enzymes of the respiratory chain and total ATP intracellular 
content. (A) Immunoblot analysis of Complex I (I-NDUFB8), complex II (II-SDHB), 
complex III (III-UQCRC2), complex IV (IV-COXII) and complex V (V-ATP5A) of the 
electron transport chain of osteoclast and control cells. HSP60 immunoblot was used for 
normalization. (B) The plots reports the densitometric quantitation (ratio of each 
protein:HSP60). Note that I-NDUFB8, II-SDHB, III-UQCRC2, and V-ATP5A were 
upregulated in osteoclast. *p<0.05, n≥3. (C) Total intracellular ATP was increased in 
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osteoclast with respect to control cells. Results were normalized to total protein content. 
**p<0.01, n=10. 
 
As a means of verification of the increased OxPhos metabolism in human 
osteoclasts, we evaluated metabolic changes that occur during 
osteoclastogenesis by analyzing oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) of living precursors and mature 
osteoclast (i.e. 7-14 days of differentiation). We found that ECAR values were 
lower in cells treated with osteoclast differentiating factors with respect to 
untreated cells, whereas OCR values were higher in osteoclast then in control 
cells, except for precursors cells (Fig. 4.6A-B). To confirm the high 
mitochondrial activity, we measured the oligomycin-sensitive OCR (mtOCR), 
the ATP coupling efficiency, and the glycolytic efficiency of mature osteoclast 
cells. We found a significantly higher mtOCR and a low glycolytic efficiency, 
with a tendency in higher ATPcoupling and lower ECAR in osteoclasts with 
respect to control cells (Fig. 6C-D).  
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Figure 4.6. Energetic metabolism during osteoclast differentiation. Osteoclasts and 
immature cells were cultured for 14 days, and baseline ECAR and OCR were measured using 
the Seahorse Flux Analyzer. Typically, after the incubation with osteoclast differentiation, 
osteoclasts are formed starting from day 7. ECAR, extracellular acidification rate; OCR, 
oxygen consumption rate; mtOCR, mitochondrial OCR. Graphs showed the ECAR (A) and 
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OCR measurements (B) at different time points of a representative osteoclast culture obtained 
from a single donor (A, B, C, D vertical lines correspond to the time of injection of 
oligomycin, FCCP, rotenone and antimycin A, 2-deoxy-glucose 100 mM respectively); (C) 
ECAR, mtOCR, and ATP coupling values of cells treated with osteoclast differentiating 
factors, or not treated, at 7 days of cultures. Average of different cultures obtained from 
different donors. Mean ±SE (*p<0.05, n=3); (D) Glycolytic efficiency (glucose 
consumption/lactate production ratio) Each graph represents the results obtained for each 
individual culture obtained from 3 different donors. *p<0.05, **p<0.01, n=5. All the results 
were normalized by total protein.  
 
4.1.3 Energetic metabolism during bone resorption 
After confirming that the energetic demand for osteoclast formation is largely 
fulfilled by the oxidative metabolism, we wondered about the metabolic profile 
of osteoclast activated to resorption. To investigate if osteoclast activity is 
mainly driven by glycolysis or OxPhos, mature osteoclasts were exposed to 
complete cell culture medium containing only glucose or only galactose as 
energetic fuel [149] and seeded on a layer of collagenous matrix. Glucose 
promotes glycolysis, whereas galactose force cells to depend on OxPhos to 
generate sufficient ATP by reducing the rate of glycolysis [150]. We found that, 
when mature osteoclasts were exposed to glucose, type I collagen degradation 
activity was significantly increased with respect to galactose (Fig 4.7A). 
Moreover, the combination of galactose with rotenone that inhibits complex I of 
electron transport chain significantly increased collagen Type I degradation 
activity with respect to cell cultures containing only galactose in the medium 
(Fig 4.7B). Notably, to evaluate the resorption activity of osteoclasts we used a 
not toxic concentration of rotenone (10 nM) (data not shown). Our results 
demonstrate that glycolysis is the key energetic pathway driving the resorption 
activity of mature osteoclasts, while oxidative metabolism is maintained to 
support other simultaneous cellular functions.  
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Figure 4.7. Glycolysis drives the activity of human osteoclasts. (A) Type I collagen 
degradation activity of osteoclast is regulated by glucose metabolism. *p<0.05, n=4.  (B) 
Inhibition of the mitochondrial complex I with rotenone 10 nM in galactose media increased 
the type I collagen degradation activity of osteoclast. **p<0.01, n=8. 
 
 
Section 2:  Lactate fuels the basal metabolism of human osteoclasts 
 
4.2.1 Expression of MCT1 increases during osteoclastogenesis  
The bone metastatic microenvironment is a cellular matrix composed of bone 
matrix and several cellular elements, including tumor cells that spread to the 
bone, bone resident cells and stromal cells. In the context of lytic bone 
metastases, osteoclast actively resorbs bone, thereby playing a primary role in 
the pathogenesis of bone metastases. To study the role of lactate and of MCT 
shuttles in the metastasis microenvironment, I first focused the analyses on MCT 
expression in osteoclast cells. Western blot analyses revealed that osteoclasts 
express high levels of MCT1, and, most importantly, the expression of MCT1 
increases during the differentiation of osteoclasts (Fig. 4.8A-B). MCT1 
expression increased during osteoclastogenesis at the mRNA level as well, as 
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confirmed by qRT-PCR analyses (Fig. 4.8C), whereas MCT4 expression was 
lower both in precursors and mature osteoclasts (Fig. 4.8C). Notably, mature 
osteoclasts were able to take up 14C-sodium lactate in a dose-dependent manner 
(Fig. 4.8D). To assess if the high MCT1 expression observed in human 
osteoclast in vitro also occurs in vivo, we analysed the expression of MCT1 in 
giant-cell tumor of bone (GCT), a benign adult human tumor characterized by 
the presence of multinucleated osteoclast-like cells [142]. The 
immunohistochemistry analyses on paraffin section demonstrated that MCT1 
was highly expressed in osteoclasts, whereas it is lower expressed by other 
bone-resident cells (Fig. 4.8E).  
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Figure 4.8. MCT expression increases during osteoclastogenesis and is relevant in giant-
cell tumor of bone. (A) Immunoblot analysis of MCT1 in precursor cells (0 days) and in 
mature osteoclast (7-14 days of differentiation). ACTB immunoblot was used for 
normalization. (B) The plot report the densitometric quantitation of MCT1:ACTB. Note that 
MCT1 increases during osteoclast differentiation from precursors cells. *p<0.05, n=3. (C) 
MCT1 and MCT4 mRNA expression in precursor and mature osteoclast. Normalization to 
TBP. (D) 14C-Lactate uptake in mature osteoclasts. Result is normalised to total protein 
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(mg/well), n=4. (E) MCT1 immunohistochemistry was performed on human Giant-cell tumor 
of bone (GCT). Note that osteoclast are strongly stained for MCT1 (brown), while other bone-
resident cells are poorly stained. Original magnification 20x. 
 
4.2.2 Cells of bone metastatic microenvironment express high levels of 
MCT4  
The expression of MCT shuttles by the cells of the bone metastatic 
microenvironment were analyzed in breast carcinoma cell lines, in MSC from 
bone marrow, and in osteoblast differentiated from MSC. As cellular model of 
breast carcinoma cells we used MDA-MB-231 and MDA-MB-231 bone met, a 
clone prone to form bone metastases when injected intracardiacally in mice 
[141]. The qRT-PCR analyses of MCT1 and MCT4 revealed a significantly 
higher expression of MCT4 with respect to MCT1 in the two breast carcinoma 
cell lines, and in MSC, whereas osteoblast present low levels of both MCT 
shuttles (Fig. 4.9A,C). We also found that breast carcinoma cell lines produced 
and released about 10 mM lactate in supernatant, thereby confirming its capacity 
to export lactate in the tumor microenvironment (Fig. 4.9B).  
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Figure 4.9. MCT expression in breast carcinoma cells, MSC and osteoblasts. (A) MCT1 
and MCT4 mRNA expression in MDA-MB-231 and MDA-MB-231bone-met cells. 
Normalization to ACTB. *p<0.05, n=3. (B) Lactate production by MDA-MB-231 and MDA-
MB-231bone-met cells was measured from cell supernatants. Results were normalised by 
total protein. p=ns, n=3. (C) MCT1 and MCT4 mRNA expression in bone marrow MSC 
(MSC t0) and human osteoblasts (HOB t1) derived from MSC. Normalization to PPIA. p=ns, 
n=5.  
 
4.2.3 Lactate fuels the basal metabolism of human osteoclasts  
Considering that osteoclast rely on OxPhos as main source for energy 
production, that MDA-MB-231 cells release high levels of lactate, and that 
osteoclasts are able to uptake extracellular lactate, we evaluated the effect of 
lactate (10 mM) on the oxidative metabolism of human osteoclasts. Metabolism 
of living osteoclasts was evaluated by mitochondrial OCR, ATP coupling of 
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mitochondria, and ECAR. We found that lactate significantly increased the 
oxidative metabolism of osteoclasts (Fig 4.10A-B), without affecting ECAR 
(Fig. 4.10C), and that lactate significantly decreased the glycolytic efficiency of 
osteoclast with respect to not treated cells (Fig 4.10D). We confirmed that 
mitochondria metabolism is increased in the presence of lactate by using the 
fluorescent probe JC-1, a vital dye that accumulates in mitochondria as a 
function of mitochondrial transmembrane potential (Δψ) (data not shown). 
Altogether, these results demonstrate that lactate increased the bioenergetics of 
human osteoclasts, since it can be used as metabolic fuel by human osteoclasts. 
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Figure 4.10. Lactate is an oxidative fuel for mature osteoclasts. Osteoclasts were treated 
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for 7 days with 10 mM sodium lactate in presence of 25 mM glucose. Their metabolic 
response was quantified using Seahorse XF96 bioanalyzer (A, B, C), and CMA600 enzymatic 
analyzer (D). *p<0.05, **p<0.01, n=3.  
  
 
Section 3: Identification and validation of housekeeping genes for gene 
expression analyses of cancer stem cells  
The metastatic microenvironment is composed of several types of cells, 
including CSC, a minority subset of tumor-initiating cells involved in metastasis 
formation and relapse. Here, I analysed the most stable housekeeping genes 
(HKG) for the normalization of qRT-PCR data direct to compare CSC and 
native tumor cells.  
 
4.3.1 RNA quality control and characterization of CSC 
Sphere cultures were established from commercially available cell lines from 3 
different sarcoma and 2 carcinoma histotypes (MG-63 for OS, RD for RS, A-
673 for ES, MDA-MB-23 for BC, and ACHN for RC), and from a fresh ES 
biopsy (ES4540).  
With the exception of cscMG-63, cscMDA-MB-231, and cscACHN, the 
stemness-like features for all the CSC cultures included in this study were 
previously characterized [92,93]. I confirmed the ability of these CSC cell lines 
to growth as floating aggregates, and the mRNA expression for KLF4, c-Myc, 
Nanog, and OCT3/4 stemness markers (Fig. 4.11) [151]. The stemness genes 
were normalised by ACTB, one of the most commonly used HKG.  
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Figure 4.11. Characterization of spheres obtained from MG-63, MDA-MB-231 and 
ACHN.  Representative images of adherent native cells and CSC floating spheres observed 
by inverted optical microscope for the different cell lines (scale bar 100 µm, left panel), and 
gene expression of stem cell markers by qRT-PCR (right panel). Normalization to ACTB. For 
cscMG-63, c-Myc **p=0.0019, KLF4 p=ns, Nanog **p=0.0010, OCT3/4 *p=0.0265. For 
cscMDA-MB-231, c-Myc **p=0.0011, KLF4 *p=0.0130, Nanog **p=0.0011, OCT3/4 
*p=0.0325. For cscACHN, c-Myc p=ns, KLF4 *p=0.0130, Nanog *p=0.0130. For adherent 
ACHN, OCT3/4 *p=0.0130. n=12. (Reproduced from Lemma S. et al, 2016. PLoS ONE 
11(2): e0149481.) 
 
 
4.3.2 Expression profile of the candidate HKG genes 
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Fifteen candidate reference genes (Table 3.1) were selected through the analysis 
of literature survey on studies on normal stem cells and tumor cells with qRT-
PCR analysis. We selected those genes that belong to different functional classes 
or pathways in order to reduce the probability to include in the analysis co-
regulated genes. The transcript profiling of the selected genes was preliminary 
analysed by Illumina Genome Analyzer sequencing. The deep sequencing 
analysis showed that the putative reference genes were stably expressed, with 
the exception of G6PD (Table 4.1, Figure 4.12A). 
 
Table 4.1. Transcriptome data from deep sequencing analysis of CSC and native cells of 
osteosarcoma  
Gene  Ensembl 
ID 
Entrez 
ID 
cscMG-
63 
MG-
63 
cscHO
S 
HOS cscSA
OS-2 
SAOS-
2 
ACT
B 
ENSG00
0000756
24 
60 13.565 13.881 13.906 14.208 13.946 14.120 
B2M ENSG00
0001667
10 
567 13.117 13.172 12.706 12.564 12.788 13.071 
G6PD ENSG00
00016021
1 
2539 10.290 8.851 11.059 10.190 11.559 10.925 
GAP
DH 
ENSG00
00011164
0 
2597 13.385 13.511 13.159 13.001 13.385 12.827 
GUSB ENSG00
0001699
19 
2990 9.778 9.271 10.630 9.549 11.996 10.151 
HMB
S 
ENSG00
0001493
97 
3145 10.035 9.041 10.511 10.912 9.905 9.744 
HPRT
1 
ENSG00
0001657
04 
3251 9.304 9.509 10.125 10.475 10.190 10.093 
PGK1 ENSG00
0001021
44 
5230 12.137 12.440 12.159 12.320 12.895 12.663 
PPIA ENSG00 5478 10.804 11.126 11.472 11.950 10.268 10.620 
 72
0001962
62 
RPL1
3a 
ENSG00
0001425
41 
23521 11.081 11.589 11.315 11.732 11.273 11.297 
SDH
A 
ENSG00
0000735
78 
6389 11.096 10.548 11.476 11.326 11.813 11.232 
TBP ENSG00
00011259
2 
6908 9.238 8.985 8.922 9.017 9.285 9.113 
TUBB ENSG00
0001962
30 
203068 13.866 14.479 14.251 14.378 14.059 14.590 
YWH
AZ 
ENSG00
0001649
24 
7534 12.379 13.023 11.812 12.737 12.437 12.641 
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Figure 4.12. Transcription profiling of the selected reference genes. (A) Heat map 
showing the relative expression of the selected genes in native cells and CSC from MG-63, 
HOS, and SAOS-2. (B). Transcriptional profile of Cycle threshold (Ct) values of candidate 
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HKG genes in CSC and native cell lines. Boxes represent lower and upper quartiles of cycle 
threshold range with the median indicated, vertical bars represent the 10th and 90th percentiles. 
In both CSC and adherent cell lines, 18S rRNA was the most highly expressed gene (lower Ct 
value), whereas G6PD was the least expressed gene (highest Ct value). (Reproduced from 
Lemma S. et al, 2016. PLoS ONE 11(2): e0149481.) 
 
We used only MG-63 as representative of the OS histotype for the following 
qRT-PCR analysis to confirm the data obtained by deep sequencing. To compare 
different mRNA transcription levels we used the threshold cycles (Ct) values. Ct 
value is the intersection between an amplification curve and a threshold line, and 
is inversely correlated with the amount of target gene present in the PCR 
reaction [152]. The 15 candidate reference genes exhibited a broad range of 
expression level. The distribution of median Ct values and percentile for each 
gene is shown in the blox plot of Figure 4.11B. Reference genes were less 
expressed in CSC compared to native cells (Table 4.2). By performing the paired 
Wilcoxon signed-rank test for each gene to evaluate the difference between CSC 
and native cells obtained from the same cells of origin, we found a significant 
difference in HKG expression between CSC and native cells for around half of 
the HKG examined (Table 4.2). 
 
 
Table 4.2. Ct values of candidate HKG genes in CSC and native cell lines 
Gene Ct values CSC  
[mean ± SD] 
Ct values native 
cell lines [mean ± 
SD] 
ΔCt values CSC 
and native cells  
[mean ± SDpooled] 
P value 
18S rRNA  10.51 ± 1.53 9.89 ± 0.84 0.62 ± 0.24 N.s. 
ACTB  21.58 ± 1.98 19.96 ± 1.42 1.62 ± 0.64 0.0277 
B2M 21.95 ± 1.22 21.63 ± 1.13 0.32 ± 0.20 N.s. 
G6PD 30.61 ± 1.14 29.82 ± 2.13 0.79 ± 0.61 N.s. 
GAPDH 20.72 ± 1.54  19.43 ± 1.01 1.29 ± 0.46 0.0277 
GUSB 28.66 ± 2.16 27.81 ± 1.04 0.85 ± 0.34 N.s. 
HMBS 27.82 ± 1.30 26.85 ± 0.87 0.97 ± 0.34 N.s. 
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HPRT1 26.82 ± 1.88 25.84 ± 1.01 0.98 ± 0.37 0.0277 
PGK1 24.80 ± 0.81 23.43 ± 0.98 1.37 ± 0.48 0.0277 
PPIA 22.27 ± 1.36 21.24 ± 0.77 1.03 ± 0.35 0.0464 
RPL13a 21.79 ± 1.64 20.51 ± 1.19 1.28 ± 0.49 0.0464 
SDHA 26.01 ± 1.17 25.58 ± 1.09 0.44 ± 0.22 N.s. 
TBP 27.32 ± 1.28 26.94 ± 0.89 0.37 ± 0.17 N.s. 
TUBB 23.00 ± 1.66 21.07 ± 1.07 1.93 ± 0.65 0.0277 
YWHAZ 23.83 ± 1.07 22.60 ± 0.77 1.23 ± 0.40 0.0277 
N.s. not significant 
 
 
4.3.3 Determination of housekeeping gene expression stability 
HKG expression stability was evaluated by using NormFinder VBA applet, the 
GeNorm software, and by calculating and comparing the coefficient of variation 
(CV) in three different groups: in (1) CSC or (2) native cells, with the aim to 
identify the most stable genes within a specific cell subtypes, and (3) in the 
pooled CSC and native cells, with the aim to identify the most stable genes to be 
considered as reference genes for the comparison of gene expression between 
CSC and native cells.  
The stability values for NormFinder and M values for GeNorm are parameters 
of stability that are inversely correlated to the expression stability of the HKG. 
All the 15 candidate reference genes had a M value lower than the threshold 
value of 1.5 (Table 4.3), which indicated that all can be considered as acceptable 
in terms of stability [147].  
1) The most stable HKG in CSC. Using the NormFinder VBA Applet, the 3 
most stable HKG resulted GAPDH, PGK1 and HMBS (from the first to the third 
stable), whereas the less stable were RPL13a, B2M and GUSB. Using GeNorm 
software, we identified YWHAZ, GAPDH and TBP as the most stable HKG, 
whereas the less stable genes were ACTB, GUSB and B2M. CV method also 
underlined that the use of ACTB should be avoided, whereas, like for GeNorm 
and NormFinder analyses, the use of PGK1 and YWHAZ is recommended. The 
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minimal number of reference genes required for normalization was determined 
by GeNorm calculation of pairwise variation (variation coefficient, V) between a 
given number of genes and the inclusion of an additional gene, and the optimal 
number of reference gene was calculated as 3 (V3/4 0.114, Fig. 4.13A). In 
conclusion, for the gene expression analyses of mRNA isolated from CSC, the 
optimal normalization factor should be calculated as the geometric mean of the 
reference targets YWHAZ, GAPDH and PGK1.  
2) The most stable HKG in native adherent cells. NormFinder analysis revealed 
that 18S rRNA, TBP, and PPIA were the three best HKG, whereas RPL13a, 
G6PD, and ACTB were worse in expression stability. Similarly, GeNorm 
identified PPIA and 18S rRNA as the two most stable HKG, followed by 
GAPDH, whereas the less stable genes were G6PD, RPL13a, and ACTB. The 
CV method suggested HMBS, TBP and YWHAZ as the three most stable genes. 
The GeNorm calculation of the variation coefficient V suggested that the 
optimal number of reference genes was 2 (V2/3 0.146; Fig 4.13B). In 
conclusion, for the native cell the optimal normalization factor should be 
calculated as the geometric mean of PPIA and TBP.  
 
Table 4.4. Ranking of the stability of the expression of candidate reference genes by 
NormFinder, geNorm, and CV analyses 
NormFinder GeNorm 
Coefficient of 
Variation 
(CV) 
Group of cells Gene 
Stability 
value Rank M value Rank CV Rank 
CSC GAPDH 0.059 1 0.500 2 0.074 11 
 PGK1 0.077 2 0.706 8 0.033 1 
 HMBS 0.095 3 0.627 7 0.047 5 
 YWHAZ 0.101 4 0.516 3 0.045 3 
 PPIA 0.102 5 0.528 4 0.061 8 
 G6PD 0.104 6 0.761 9 0.037 2 
 TUBB 0.119 7 0.611 6 0.072 10 
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 ACTB 0.138 8 1.095 14 0.092 14 
 HPRT1 0.149 9 0.921 12 0.070 9 
 SDHA 0.151 10 0.799 10 0.045 4 
 B2M 0.153 11 1.179 15 0.055 7 
 TBP 0.160 12 0.456 1 0.047 6 
 
RPL13a 
 0.162 13 0.850 11 0.075 13 
 18S rRNA 0.178 14 0.583 5 0.146 15 
 GUSB 0.282 15 1.022 13 0.075 12 
Native cells 18S rRNA 0.154 1 0.290 1 0.085 15 
 TBP 0.158 2 0.498 4 0.033 2 
 PPIA 0.159 3 0.296 2 0.036 4 
 SDHA 0.168 4 0.653 7 0.043 8 
 GAPDH 0.183 5 0.345 3 0.052 10 
 B2M 0.187 6 0.689 8 0.052 11 
 HMBS 0.190 7 0.786 11 0.032 1 
 HPRT1 0.191 8 0.729 9 0.039 6 
 YWHAZ 0.199 9 0.554 5 0.034 3 
 TUBB 0.201 10 0.596 6 0.051 9 
 GUSB 0.207 11 0.762 10 0.037 5 
 PGK1 0.219 12 0.809 12 0.042 7 
 RPL13a 0.226 13 0.961 14 0.058 12 
 G6PD 0.229 14 1.092 15 0.071 14 
 ACTB 0.257 15 0.888 13 0.071 13 
CSC and native 
cells 
(pooled) GAPDH 0.124 1 0.484 3 0.086 12 
 PPIA 0.134 2 0.437 1 0.066 8 
 HMBS 0.141 3 0.689 6 0.051 4 
 TBP 0.149 4 0.624 5 0.046 1 
 PGK1 0.153 5 0.786 8 0.052 5 
 YWHAZ 0.161 6 0.588 4 0.055 6 
 G6PD 0.165 7 1.167 15 0.067 10 
 18S rRNA 0.168 8 0.470 2 0.143 15 
 TUBB 0.168 9 0.735 7 0.091 13 
 SDHA 0.172 10 0.821 9 0.050 3 
 HPRT1 0.173 11 0.858 10 0.066 9 
 B2M 0.182 12 1.037 13 0.050 2 
 ACTB 0.192 13 1.104 14 0.103 14 
 RPL13a 0.198 14 0.979 12 0.074 11 
 GUSB 0.238 15 0.918 11 0.066 7 
 
 78
 
Fig 4.13. GeNorm evaluation of the minimal number of genes and validation of the 
identified top-ranked HKG genes for qRT-PCR normalization. The minimal number of 
genes required for data normalization was evaluated by pairwise variation (Vn/n +1) in (A) 
CSC, (B) native cells, (C) in the CSC and native cell lines from all tumors, (D) from sarcoma 
and (C) from carcinomas. A variation coefficient (V) below 0.15 indicates the optimal number 
of genes required for data normalization. (Reproduced from Lemma S. et al, 2016. PLoS ONE 
11(2): e0149481.) 
 
3) Finally we performed the analysis of CSC and native pooled cells in all 
 79
tumors (A), in sarcoma (B) and carcinoma (C).  
(3A) In CSC and native cells from all tumors, NormFinder identified GAPDH, 
TBP, and PPIA as the three most stable HKG, whereas ACTB, RPL13a and 
GUSB were the less stable. PPIA and GAPDH were also confirmed by GeNorm 
analysis, along with 18S rRNA. Again, ACTB was the last gene in stability for 
the GeNorm analysis, along with B2M and G6PD. The CV evaluation suggested 
TBP, B2M, and SDHA (Table 4.3). GeNorm recommended the use of 4 HKG 
for accurate gene expression analysis (V4/5 < 0.15; Fig. 4.13C). Consequently, 
the normalization factor should be calculated as the geometric mean of TBP, 
PPIA, HMBS, and YWHAZ or GAPDH.  
 (3B) In CSC and native cells from sarcoma, the NormFinder software identified 
GAPDH, YWHAZ and 18S rRNA as the most stable genes. GAPDH and 
YWHAZ were identified as the best HKG also by the GeNorm analysis. The CV 
method showed that HMBS, TBP, and SDHA had the best rank position (Table 
4.4). The optimal number of reference targets is 2 (V2/3 0.143, Fig. 4.13D). In 
conclusion, the optimal normalization factor can be calculated as the geometric 
mean of YWHAZ and GAPDH.  
(3C) The analysis of HKG stability in carcinoma revealed that PPIA, HMBS and 
RPL13a were the most stable HKG for NormFinder. GeNorm also confirmed 
PPIA and RPL13a as most stable targets by GeNorm, followed by 18S rRNA, 
whereas the CV method suggested B2M, TBP and G6PD (Table 4.4). The 
GeNorm calculation of the coefficient V suggested that 2 HKG are sufficient for 
normalization (V2/3 0.084, Fig. 4.13E). In conclusion, the optimal 
normalization factor in this case should be calculated as the geometric mean of 
two of the following genes, PPIA, HMBS or RPL13a. 
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Table 4.4 Ranking of the stability of the expression of candidate reference genes by 
NormFinder, geNorm, and CV analyses in CSC and native cells from carcinoma and 
sarcoma tumors 
NormFinder GeNorm 
Coefficient of 
Variation 
(CV) 
CSC and native 
cells (pooled) Gene 
Stability 
value Rank M value Rank CV Rank 
Sarcoma GAPDH 0.299 1 0.386 1 0.049 9 
 YWHAZ 0.346 2 0.434 3 0.036 4 
 18S rRNA 0.349 3 0.573 6 0.078 15 
 PPIA 0.368 4 0.446 4 0.036 5 
 TUBB 0.478 5 0.420 2 0.049 10 
 TBP 0.489 6 0.607 7 0.033 2 
 SDHA 0.489 7 0.525 5 0.035 3 
 PGK1 0.503 8 0.656 8 0.037 6 
 HMBS 0.562 9 0.697 9 0.031 1 
 HPRT1 0.722 10 0.770 10 0.045 8 
 GUSB 0.754 11 0.880 12 0.043 7 
 ACTB 0.771 12 1.160 15 0.077 14 
 B2M 0.826 13 0.834 11 0.059 11 
 RPL13a 0.894 14 0.978 13 0.073 13 
 G6PD 0.907 15 1.074 14 0.059 12 
Carcinoma PPIA 0.055 1 0.150 1 0.069 9 
 HMBS 0.072 2 0.453 10 0.060 5 
 RPL13a 0.088 3 0.193 3 0.075 11 
 ACTB 0.091 4 0.390 8 0.092 13 
 HPRT1 0.093 5 0.368 7 0.073 10 
 18S rRNA 0.093 6 0.164 2 0.144 15 
 TBP 0.094 7 0.417 9 0.053 2 
 GAPDH 0.103 8 0.298 4 0.088 12 
 GUSB 0.104 9 0.315 5 0.066 7 
 G6PD 0.140 10 0.521 11 0.054 3 
 B2M 0.140 11 0.785 15 0.036 1 
 YWHAZ 0.160 12 0.341 6 0.067 8 
 TUBB 0.160 13 0.713 14 0.103 14 
 PGK1 0.182 14 0.647 13 0.064 6 
 SDHA 0.219 15 0.572 12 0.059 4 
 
 
4.3.4 Validation of the identified HKG in the CSC model  
In gene expression evaluation, the use of suboptimal HKG can generate 
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erroneous results or can hide a difference in gene expression. This is particularly 
important for genes that slightly change between two populations of cells, such 
as CSC and native cells.  
We analyzed the expression of the stemness genes c-Myc, KLF4, Nanog, and 
OCT3/4 that were previously normalized to ACTB (Fig. 4.11), with the 
identified top-ranking HKG for CSC and native cells, in sarcoma and 
carcinoma, respectively (GAPDH and YWHAZ for sarcoma, and PPIA and 
HMBS for carcinoma). Some of the stem-related genes considered showed an 
improved robustness of statistical analysis performed with the normalization 
with the most stable HKG, in respect with ACTB (Fig. 4.14). 
 
 
Fig 4.14. Validation of the identified housekeeping genes. The effect of gene expression 
normalization with optimal HKG was investigated on CSC and native cells from MG-63 and 
ACHN. (A) For the osteosarcoma cell line, the expression of the stem cell markers Nanog and 
cMyc were evaluated and normalized to the geometric mean of GAPDH and YWHAZ. 
***p=0.0007 for Nanog, ***p=0.0003 for c-Myc. (B) For the ranal carcinoma cell line, the 
expression of Nanog and cMyc was normalized to the geometric mean of PPIA and HMBS. 
**p=0.0043 for Nanog. n=6. (Reproduced from Lemma S. et al, 2016. PLoS ONE 11(2): 
e0149481.)
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5. DISCUSSION 
 
In physiological condition, bone homeostasis is maintained by a delicate 
metabolic equilibrium in bone-relating cells [3]. Osteoclast and osteoblast 
functions must be tightly regulated to maintain homeostasis. Pathological 
increases in osteoclast activity induce trabecular bone erosion that result in 
various diseases, including osteolytic metastases [153]. The development of lytic 
bone metastasis relies on an exquisite interplay between tumor cells and the 
machinery orchestrating bone remodeling. Cytokines and hormones produced by 
the primary tumor are known activators of osteoclastogenesis and osteoclast-
mediated bone resorption [17,19,154]; however their therapeutic inactivation is 
only partially effective, possibly due to the inability of the treatments to interfere 
with the metabolic pathways that regulate the behavior and the cross-talk 
between metastatic cells and osteoclasts. In this study, we focused on the 
metabolic adaptation that occurs in the metastatic microenvironment.  
First, we focused on the basal metabolism of human osteoclast, demonstrating 
that osteoclasts mainly rely on oxidative metabolism for differentiation. 
Indications about the high metabolic activity of osteoclasts are already apparent, 
including the presence of a large ATP pool needed for serial stages of 
osteoclastogenesis and for the fusion of mononuclear precursors to form 
multinucleated osteoclasts [33]. We analyzed osteoclast metabolism by using 
primary cell culture of human osteoclasts from PBMC. As proof-of-principle 
that mature osteoclasts are mitochondria-rich cells [33], we carried out a series 
of experiments to elucidate the role of mitochondria in osteoclast differentiation. 
We confirmed that human osteoclasts present increased mitochondria mass and 
abundant mitochondria, increased in size and rich of cristae, especially if 
compared with their monocyte precursors. The overall morphology of the 
 83
mitochondrial network of mature osteoclasts displayed a complex reticular 
pattern. Mitochondrial networks spread throughout the cells, from the 
perinuclear region to the peripheral basal domain. The formation of cluster of 
mitochondria around the nuclei may be important to efficiently fulfill to 
biosynthetic functions, whereas the complex reticulum in the basal domain may 
be important for generating ATP in the peripheral regions of the cell. 
Considering that mitochondrial biogenesis in associated with an increase 
expression OxPhos enzymes [35], that cristal membranes are the principal sites 
of OxPhos  [155], and that mitochondrial networks are important for generating 
ATP in all part of the cell [156], we verified if mitochondrial metabolism is the 
main bioenergetics driving energy production in mature osteoclasts. 
Consistently, we found that osteoclasts present high levels of mitochondrial 
OCR, and low glycolytic efficiency. In control cells, we found a glycolytic 
efficiency close to 2, which occurs when all the glucose consumed by a cell is 
converted to lactate, bypassing other metabolic pathways that could utilize 
glucose or its metabolites. In line with these results, we demonstrated that 
osteoclasts present increased expression of the complexes of respiratory chain, 
and high intracellular ATP content, proving that osteoclasts rely on oxidative 
metabolism for energy production to support the biosynthesis of components 
demanded for differentiation. Notably, despite results obtained with primary cell 
cultures of human osteoclasts are usually characterized by a huge variability, we 
found considerable reproducibility, thereby strongly supporting our conclusions.  
Based on our observations, we conclude that osteoclasts are in a high energetic-
state sustained by mitochondrial metabolism that might support all the high 
energy-consuming functions, including bone resorption. Accordingly, we 
investigated the metabolic pathway underlying osteoclast activity by using 
glucose or galactose as energy sources. To gain insights into the metabolic 
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pathway that fuels osteoclast activity, we adjusted media composition with 
different metabolites, like glucose or galactose as energy sources [149]. The 
oxidation of galactose to pyruvate through glycolysis yields no net production of 
ATP, inducing cells to rely on OxPhos to produce energy [157]. We found that 
when mature osteoclast were cultured with glucose or galactose, they 
preferentially resorbed type I collagen in presence of glucose, proving that 
glucose is an essential carbon sources for the acquisition of the resorption 
activities. Consistently, the combination of galactose and complex I inhibitor 
rotenone not impaired osteoclast activity, whereas collagen degradation was 
induced. The regulatory effect of glucose on osteoclast activity is consistent with 
a previous report showing that glucose regulates the bone resorption of chicken 
osteoclast at physiological concentration [158]. Other study demonstrates that 
glucose initiates a series of signaling events that dynamically activates the 
expression of V-ATPase to stimulate resorption [159]. V-ATPase interact with 
the glycolytic enzymes phosphofructokinase-1 though the A-subunit [160], and 
with aldolase though the E-subunit [161], suggesting a direct coupling between 
the ATP-generating glycolytic enzymes and the ATP-hydrolyzing proton pumps. 
Proton pumps and ion transporters works hard to transport protons in the 
cytoplasm of bone resorbing osteoclasts, which then are conveyed into acidic 
vesicles and released into the extracellular compartment of the resorption lacuna 
[45,47]. Protons secreted into the resorption lacuna allow the dissolution of 
hydroxyapatite crystals, and generate the acid environment necessary for the 
digestion of organic bone matrix by acid proteases [3]. Considering that two 
protons and two ATP are generated for every molecule of glucose that convey in 
the glycolytic pathway, it is reasonable to imagine that many proton pumps and 
glycolytic enzymes can assembly to the ruffled border to compartmentalize ATP 
and protons generation at functionally-distinct membrane compartments. In 
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osteoclast, the ruffled border present distinct sub-domains for secretion of acidic 
vesicle [162], where probably glycolytic enzymes provide ATP to proton pumps 
that actively convey protons into the resorption lacunae. In a more complete 
visualization of metabolic state of osteoclast during resorption, we presume that 
mitochondria networks provide energy in all part of the cell, thereby supporting 
osteoclast survival, whereas the direct coupling between glycolysis and proton 
pumps allow a more efficient resorption activity in distinct subdomains of the 
ruffled border. We expect that osteoclast relies on a spatial and temporal 
compartmentalization of metabolism to support specific cellular functions in 
particular cellular subdomains [163]. As previously demonstrated for angiogenic 
endothelial cells, glycolytic enzymes compartmentalize in lamellipodia and 
filopodia to allow rapid generation of ATP during the high-energy consuming 
processes of cell motility [164]. With a similar mechanism, during the energy-
consuming process of bone resorption, osteoclast arrange the cytoskeleton to 
migrate on bone, and to insert the V-ATPases into the ruffled membrane [165], 
and it is likely that this rearrangement of microtubule and membrane transporter 
allow the compartmentalization of protons to the front of migration and 
resorption. Additional studies are urgently needed to highlight the role of 
metabolic compartmentalization in the regulation of specific cellular function of 
osteoclasts.  
Then, we focused on the effect of the high-energy metabolite lactate produced 
by highly glycolytic tumor cells on osteoclast metabolism. Current knowledge 
suggests that lactate, rather than a mere metabolic waste product, is an effective 
metabolic fuel for oxidative cells, acting as a paracrine-signaling agent both on 
tumor and host cells. Previous studies demonstrated that lactate could be up take 
by tumor-associated stromal cells to supports tumor progression [119,139]. We 
demonstrated that mature osteoclast relies on oxidative metabolism to support 
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the energy-associated biosynthetic functions necessary to osteoclast formation. 
The excess of lactate produced by highly aggressive glycolytic tumor cells that 
spread to the bone can be taken up from osteoclast in the bone metastatic 
microenvironment through MCT1 expression on the plasmamembrane. We 
demonstrated that osteoclast expressed high levels of MCT1, and low levels of 
MCT4. Notably, the expression of MCT1 increased during osteoclastogenesis, 
and MCT1 promote the dose-dependent up take of lactate from the extracellular 
to intracellular compartment of mature osteoclasts. Most importantly, the high 
MCT1 expression observed in human osteoclast cell culture in vitro is consistent 
with its expression by giant osteoclasts in GCT lesions in vivo. GCT is a 
histologically benign osteolytic tumor characterized by prominent osteoclast-
like giant cells, and mononuclear osteoclast precursors [142,166]. Indeed, these 
finding demonstrated that MCT1 expression is predominant in osteoclast cells, 
both in vitro and in vivo, and that the MCT1 shuttle is actively involved in 
lactate uptake in mature osteoclasts. Coherently, MDA-MB-231 breast 
carcinoma cells and MDA-MB-231 bone met cells prone to form bone 
metastases, expressed high levels of MCT4, that seem to be higher in the cell 
line prone to form bone metastases, and significantly lower levels of MCT1; 
both carcinoma cell lines produced and released high levels of lactate (10 mM) 
in cell supernatant. Also bone marrow derived MSC expressed notable levels of 
MCT4, and lower levels of MCT1, whereas osteoblast cells express low levels 
of both transporters. According to the leading hypothesis, we investigated the 
effect of lactate produced by highly glycolytic tumor cells on oxidative 
metabolism of osteoclasts. Consistently, we found that lactate acts as a 
metabolic fuel in mature osteoclasts, promoting the mitochondrial OCR, the ATP 
coupling of mitochondria, and reducing the glycolytic efficiency, without 
affecting the ECAR. These results supports our hypothesis of the metabolic 
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symbiosis of the bone metastatic microenvironment [167], where the highly 
glycolysis-dependent breast carcinoma cells release high concentration of lactate 
through MCT4 in the extracellular space, and osteoclasts take up lactate through 
the MCT1 shuttle (Fig. 5.1). Once entered into the cytoplasm, lactate fuels the 
TCA cycle that supports ATP production and the oxidative metabolism of 
osteoclasts. Similarly, stromal cells exposed to oxidative stress in the BM tumor 
microenvironment can switch to a more glycolytic metabolism, thereby 
releasing high amounts of lactate, as well [123]. As demonstrated in other tumor 
models [168], lactate uptake by tumor-supporting endothelial cells support 
angiogenesis of the tumor bulk. It is reasonable to postulate that, with a similar 
mechanisms, lactate exchange between cells of the bone metastatic 
microenvironment could act both as a signaling molecule to support tumor 
aggressiveness, and as a metabolic intermediate that fuels the basal metabolism 
of osteoclasts to further increase oxidative respiration and ATP production.  
Taken together, these data strongly support our hypothesis that in physiological 
conditions OxPhos per se is crucial to sustain osteoclastogenesis and mature 
osteoclast survival, whereas a glycolytic switch drive the resorption activity of 
human osteoclasts. The coordination between these metabolic pathways sustains 
the perfect balance from mature osteoclast formation to the acquisition of bone 
resorption ability. However, when metastatic tumor cells spread to the bone, 
they destroy the balance between bone-resident cells to support tumor cell 
survival and proliferation in the bone microenvironment. Though the metabolic 
reprogramming of bone resident cells, tumor cells activate osteoclast, thereby 
leading to a more aggressive tumor phenotype. Further studies are urgently 
needed to elucidate the role of extracellular lactate on the metastatic 
microenvironment.  
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Figure 5.1 Lactate exchange between highly glycolytic cells and osteoclasts in bone 
microenvironment supports tumor aggressiveness. 
 
 
In the complex metastatic microenvironment, CSC resides in a niche within the 
tumor bulk, i.e. a physiologically defined supportive microenvironment, where 
they interact with other malignant cells leading to a more aggressive tumor 
phenotype. The evolving concept of CSC has attracted much attention, and 
characterization of CSC has led the way to novel prospective for anticancer 
therapies. To study the molecular phenotype of CSC and the underlying cellular 
mechanism of tumorigenesis, the analysis of gene expression phenotype of 
native tumor cells and CSC is pivotal. However, despite the recent increasing 
interest in CSC, an accurate selection of reference genes to a robust 
normalization of expression data is still missing. We identified and validated the 
most stable HKG among 15 candidate reference genes for the normalization of 
qRT-PCR data. We used a panel of CSC and native cell lines from different 
human sarcoma histotypes, including a tumor primary culture derived from a 
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human Ewing’s sarcoma biopsy, and from breast and renal carcinoma. Breast 
carcinoma frequently metastasizes to the bone in the late phases of disease, with 
devastating consequences for cancer patients. We selected the HKG to be 
included in this study through a literature survey on the reference genes used for 
the normalization of qRT-PCR data from normal stem cells [143,169]. Among 
the normal stem cells, we included MSC [170,171], because they are part of the 
bone metastatic microenvironment, and represent the most likely candidate cell 
of origin for osteosarcoma and Ewing’s sarcoma [172,173], and tumor cells 
[174,175].  
As a preliminary analysis of the selected candidate reference genes, we used 
deep sequencing data, and were able to confirm that the gene expression profile 
of the selected genes was stable. Then, the expression of the selected genes was 
validated with qRT-PCR, and we found a broad expression pattern. First of all, 
we analyzed the homogeneity of expression of the selected HKG in CSC and 
native cells using the paired Wilcoxon signed-rank test. We found significant 
difference in gene expression for more than one half of the examined HKG. To 
evaluate the stability of HKG we first analyzed our data by calculating and 
comparing the coefficient of variation. Afterwards, we validated the results 
using NormFider and GeNorm. NormFinder determines the stability value using 
a model-based approach [59]. GeNorm calculates the expression stability of a 
gene based on the average pairwise variation among all reference genes [146]. 
The application of 3 different methods of gene stability evaluation could reduce 
errors associated with a single software, and could avoid the selection of co-
regulated transcripts. We used GeNorm also to determine the minimal number of 
HKG for accurate normalization. We analyzed the most stable HKG in three 
groups of data: in CSC, in native cells, and in the CSC and native cells pooled 
group. By calculating the overall best ranked HKG from the CV, GeNorm and 
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NormFinder analyses we found that PGK1, YWHAZ, and GAPDH were the 
most stable HKG for the comparison of CSC expression data, whereas the most 
stable HKG for native cells were PPIA and TBP. When we considered CSC and 
native cells with all the tumor types pooled together, we identified TBP, PPIA, 
HMBS and YWHAZ or GAPDH as HKG that should be used for qRT-PCR 
normalization. The most stable HKG for the CSC and native cells obtained only 
from sarcoma were GAPDH and YWHAZ, whereas for carcinoma we identified 
PPIA, HMBS or RPL13a. Our evaluation of HKG stability also suggested that 
ACTB and B2M, two of the most commonly used HKG used in qRT-PCR 
analyses [174-176], but also RPL13a, ranked among the last position in all the 
considered conditions, suggesting that these HKG could be unsuitable for the 
normalization of qRT-PCR data. Adversely, in carcinoma, RPL13a ranked 
between the most stable HKG in CSC and native cells. Therefore, appropriate 
HKG should be selected in relation to the tumor investigated. Moreover, the 
analysis of stemness genes KLF4, c-Myc, Nanog, and OCT3/4 to ACTB rather 
than to the most stable HKG in CSC and native cells, clearly demonstrated that 
normalization to the suboptimal HKG can lead to a complete loss of information 
about the stamness capacity of CSC, or can hide difference in gene expression 
between CSC and native cells. Taken together, our results demonstrate that 
proper reference genes should be appropriately selected under different 
experimental conditions. We recommend to use at least two of the suggested 
HKG to normalize qRT-PCR-based gene expression analyses of human CSC and 
native cells. 
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6. CONCLUSION  
 
Bone metastases are composed of a combination of tumor-associated stromal 
cells, osteoblasts, osteoclasts, CSC, and tumor cells, and the metabolic 
influences between these different cell types promote tumor progression and 
lesions formation. To investigate the metabolic symbiosis of lytic bone 
metastases, we first focused our attention on the basal metabolism of human 
osteoclast, demonstrating that human osteoclast display an oxidative basal 
metabolism that supports osteoclast differentiation from hematopoietic 
precursors. A glycolytic switch drives the acquisition of resorption activity of 
osteoclasts, suggesting that mitochondrial metabolism and glycolysis co-
coordinately regulates osteoclastogenesis and the activation of bone resorption. 
Understanding the metabolic adaptations underling the coordination of 
bioenergetics in human osteoclast differentiation and function could provide 
novel opportunities for therapeutic intervention on metabolic bone diseases 
caused by osteoclastic dysfunction, in particular lytic bone metastasis.  Notably, 
we found that in the bone metastatic microenvironment, lactate derived from 
highly glycolytic tumor cells fuels the oxidative metabolism of human 
osteoclast, leading to a more aggressive tumor phenotype, demonstrating that 
cancer cells and bone-resident cells sustain each other in a metabolic symbiosis 
aimed to support the metabolic needs of tumor bulk.   
The role of CSC in metastatic cancer is still under investigation. Future studies 
will focus on the dialogue between CSC, osteoclasts and other malignant-
associated cells to elucidate the role of the metabolic symbiosis in lytic bone 
metastasis.  
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